Development of the application of speciation in chemistry by Kiss, Tamás et al.
'Compuscript edited Dec. 02'  
Development of the Application of Speciation in Chemistry 
 
Tamás Kiss a,b,*, Éva A. Enyedy a, Tamás Jakusch a 
a Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7, H-
6720 Szeged, Hungary 
b MTA-SZTE Bioinorganic Chemistry Research Group, University of Szeged, Dóm tér 7, H-
6720 Szeged, Hungary 
 
Contents 
Abstract 
1. Definitions of speciation and fractionation 
2. Speciation in inert and labile chemical systems 
2.1. Labile systems 
2.2. Inert systems 
3. Development of the application of speciation in chemistry 
3.1. Species distribution calculations from equilibrium constants 
3.2. Parallel application of speciation and solution structural investigations 
3.2.1. UV-visible, circular dichroism, and fluorescence spectroscopy 
3.2.2. Nuclear magnetic resonance spectroscopy 
3.2.3. Electron paramagnetic resonance spectroscopy 
3.2.4. Mass spectrometry 
3.3. Modeling calculations in biological or environmental systems using stability constants 
and their experimental confirmation 
4. Examples of the application of speciation: analysis and modeling calculations 
4.1. Chemical speciation in trace analytical and environmental chemistry 
4.2. Chemical speciation of Al(III) and Fe(III) in water and biology 
4.2.1. Hydrolysis of toxic and essential metal ions: Al(III) and Fe(III) 
4.2.2. Role of human blood serum in transport and distribution processes 
4.2.3. Serum speciation by Al(III) and Fe(III) ions 
4.3. Chemical speciation in medicine 
4.3.1. Biospeciation of antidiabetic vanadium(IV, V) and zinc(II) complexes 
4.3.1.1. Interactions of V(IV)O and V(V) with transferrin 
4.3.1.2. Interaction of V(IV)O with human serum albumin 
4.3.1.3. Speciation of VO(IV) in blood serum 
4.3.2. Speciation of V(V) in blood serum 
4.3.3. Speciation of Zn(II) in blood serum 
4.4. Biospeciation of anticancer metal complexes in blood serum 
4.5. Speciation investigations with a magnetic resonance imaging contrast agent 
4.6. Kinetic aspects of speciation in biology 
4.6.1. Speciation of Al(III) in blood serum: citrate vs. phosphate 
4.6.2. Speciation of Ca(II) in saliva 
4.6.3. Interactions of Pd(II) complexes with nucleotides and thioether ligands 
4.6.4. Transport of Cu(II) from complexes with His-containing peptides to Cys 
4.6.5. Anticancer Ru(III) complexes in blood serum 
5. Outlook 
Acknowledgements 
References 
* Corresponding author. Tel.: +36/36-62-544-337 
E-mail address: tkiss@chem.u-szeged.hu 
 
Abstract 
This review provides definitions and examples of chemical speciation, as well as giving 
details of the differences in speciation between labile and inert systems. By moving from the 
simple to the complex, starting with simple species distribution calculation methods based on 
solution structural studies, this review progresses to modeling calculations that are applicable 
to “real-world” systems. The biological and or medicinal speciation of the following metal 
ions are discussed (modeling and experimental confirmation of the calculation results as well 
as kinetic aspects of their changes in speciation): Al(III), Fe(III), Ga(III), Gd(III), Ru(III), 
Ca(II), Cu(II), Pd(II), V(IV)O, V(V), and Zn(II)). Brief introductions are also given to trace 
analytical and environmental speciation. The current status and future possibilities of 
speciation studies (evaluation and prediction of speciation data), data collection, and 
databases are also critically discussed. 
 
Keywords: biospeciation, equilibrium model, human serum, kinetic aspect of speciation, 
modeling calculation, spectroscopy  
 1. Definitions of speciation and fractionation 
The term “speciation” is generally used to indicate the analytical activity/concentration 
when identifying chemical species and to measure their distribution. Thus, speciation is used 
to describe the distribution of species in a particular sample, where it is synonymous with the 
“species distribution,” e.g., “the bioavailability of aluminum depends strongly on its 
speciation” [1]. An element may be present in different chemical forms in terms of the 
isotopic composition, oxidation state, and type of binding ligand (solvent molecules, 
inorganic or organic small molecules, macromolecules, labile or inert bound ligands, etc.). For 
instance, as described in detail later, the hydrolysis of the Al(III) ion in equilibrium solution 
can yield numerous species depending on the pH and concentration, such as [Al(OH)]2+, 
[Al(OH)2]
+, Al(OH)3, [Al(OH)4]
–, [Al2(OH)2]
4+, [Al3(OH)4]
5+, and the oligonuclear 
[Al13O4(OH)24]
7+ [2], where thermodynamic equilibrium/formation constants characterize 
their stability in solution [3]. 
Another example is when the oxidation state of an element profoundly affects its 
toxicity. Thus, the more reduced species of As are the most toxic as follows: arsine (AsH3) > 
arsenite (As(III)) > arsenate (As(V)) [4]. The oxidation state may also have a strong impact on 
the absorption and elimination features of a metal ion. The Fe(II) ion is soluble under 
physiological conditions and transported freely across membranes, whereas Fe(III) does not 
enter cells and is more prone to hydrolysis in biological systems [5]. The uptake of iron from 
Fe(III)-containing species probably involves decomposition, reduction, and transport into the 
cell in the form of Fe(II) [6]. It should be noted that iron is found in both Fe(II) and Fe(III) 
oxidation states in the human body, where the transport and storage processes often involve 
redox transformation of the metal ion. 
It is often not possible to determine the concentrations of different chemical species that 
comprise the total concentration of an element in a given sample. For example, in many cases, 
the presence of a large number of individual species (e.g., in metal-humic acid complexes, 
metal-fulvic acid complexes, or metal complexes in biological fluids) can make it practically 
impossible to determine their speciation. In these cases, it may be useful to identify the 
various classes of species of an element in order to determine their summed concentration in 
each class [7]. This fractionation process can be based on many different properties of the 
chemical species, such as their size, molecular mass, solubility, charge, and affinity. 
Fractionation may involve actual physical separation, e.g., filtration or size-exclusion 
chromatography. It is useful to measure the total concentration of the element in each fraction 
in order to verify the mass balance. In some situations, the fractions can be analyzed further 
for individual species based on subsequent analyses and calculations. 
For instance, the total Al content of natural waters is not relevant to their harmful 
biological effects. However, Al(III) binds to inorganic ligands and low molecular mass 
(LMM) organic molecules to yield toxic forms of this metal ion. These forms are mobile and 
can be absorbed more easily by organisms, before being transported within biological systems 
to cause harmful biological effects. Metal ions bound to high molecular mass (HMM) 
bioligands are in a much more sluggish environment, so they are less able to react with 
endogenous molecules in biological fluids or cells. 
It should be noted that all the basic definitions and technical terms used in this study 
regarding complex formation equilibria (such as component, binary complex, and conditional 
stability constant) were specified in previous studies [8-11].  
 
2. Speciation in inert and labile chemical systems 
2.1. Labile systems 
In labile systems, all equilibria (at least one) are always reached. Fast equilibrium 
processes make it impossible to study the pure individual compounds in all conditions. One of 
the simplest examples is the dimerization equilibrium of nitrogen dioxide, where only N2O4 
forms under normal pressure and at < 263 K, whereas the NO2 form exists at > 413 K. The 
two species are inseparable at temperatures between these limits and an equilibrium state is 
always reached [12a]. An important characteristic of these labile systems is the equilibrium 
constant(s), which depends on various conditions, such as the temperature (T), pressure (p), 
solvent, and ionic strength (I). The classic example of a labile system comprises 3d5-3d10 
divalent transition metal ions, which form labile complexes, with a few rare exceptions. For 
example, these metal ions (M) form complexes with simple monodentate anions (L), such as 
halides and pseudohalides, with different compositions, e.g., ML, ML2, and ML3. The first 
description of this stepwise complex formation was published by Bjerrum [13] and its 
mathematical model can be adapted by characterizing the acid-base properties of multivalent 
acids and bases. 
However, equilibria (and labile systems) are observable “everywhere,” such as in 
solvents (e.g., autoprotolysis of water and ammonia) as well as in organic (e.g., ester 
formation) and inorganic compounds (e.g., mixtures of boron-halides [12b] and Fe(III)-Fe(II) 
redox equilibria) in biochemistry (Michaelis–Menten kinetics). 
Complicated labile systems are described by their composition matrix [14a], where each 
component belongs to one column and each row represents one species with a unique 
composition. The elements of the matrix are stoichiometric numbers and each species should 
be described by its formation (overall/cumulative stability) constant (log ). Table 1 shows 
two representative component matrices. Binary, ternary, or quaternary systems are considered 
if the number of components is 2, 3, or 4, respectively. 
 
Table 1 
Two representative component matrices: a: the binary system of H+GlyGly and b: the 
ternary system of H+GlyGly  Cu(II); data taken from Ref. [15] (I = 0.2 M KCl, t = 25C) 
a H+ GlyGly log   b H
+ GlyGly Cu(II) log  
LH 1 1 8.13  CuL 0 1 1 5.56 
LH2 2 1 11.30  CuLH-1 –1 1 1 1.33 
     CuLH-2 –2 1 1 –8.04 
     CuL2H-1 –1 2 1 4.46 
 
These matrices can be used to predict the individual concentrations (the speciation) of 
all the species formed in any set of component concentrations (see Section 3.1). As the 
determination of speciation is equal in practice to the determination of the composition matrix 
with the formation constants, and many individual species distribution (a “speciation”) can be 
calculated from this matrix, then the word “speciation” sometimes has a second meaning, 
which is the composition matrix itself (including the formation constants). 
Labile systems are first studied in fixed conditions (constant T, p, or I), starting from the 
simplest binary systems and possibly without any matrix effect, by using non-invasive (which 
does not alter the equilibrium state) methods such as potentiometry or spectroscopy. The 
concentrations of the species measured under different conditions or component 
concentrations can be used to determine the formation constants (log ). If sufficient data are 
obtained, they can be used to perform modeling calculations in order to describe real/complex 
systems in any experimental conditions. The result of these calculations may be confirmed by 
structural investigation methods. 
 
2.2. Inert systems 
In practical completely inert systems, there is no component exchange between the 
species, with no association and dissociation processes, and thus the species are separable 
from each other. For example in a mixture of H2-D2 in ambient conditions, there are no 
species such as DH and their physical separation is possible. By contrast, DHO also appears 
in the labile D2O-H2O system and the separation of various species is much more 
complicated. For complexes of certain 3d metal ions, such as Cr(III) (d3) and Co(III) (d6), the 
ligand exchange reactions are very slow, which were studied extensively by Werner [16]. The 
crystal and ligand field theory [17] can explain the lability and inertness of different transition 
metal ions. 
In inert systems, there is (usually) no suitable data set for use in speciation prediction or 
modeling calculations, so further analyses in other experimental conditions are required to 
determine sufficient information about all the species that can be formed. In these systems, 
speciation refers to the concentrations determined or the concentration ratios of the species 
identified. In order to determine the concentration matrix in “real” samples, any type of 
analytical method can also be used, even a destructive one. The most frequently applied 
method is chromatography [18]. It should also be mentioned that there is no connection 
between lability, which is a kinetic term, and thermodynamic stability [19]. 
Many real-world systems lie somewhere between complete lability and inertness. This 
simply means that it takes more time to reach complete equilibrium, e.g., the HVO4
2–-H+ 
system is considered labile at pH > 7, whereas decavanadates are formed at pH < 7, which 
decompose quite slowly. This system could take more than a day to reach a true equilibrium. 
In addition, it is impossible to predict the As(III)/As(V) ratio in a simple way based 
merely on the As content, but if we know the total concentration of inorganic As(V), the 
speciation of As(V) (forms such as H3AsO4, H2AsO4
–, HAsO4
2–, or AsO4
3–) can be calculated 
at a given pH using the formation constants of the species at the different protonation states. 
 
3. Development of the application of speciation in chemistry 
3.1. Species distribution calculations from equilibrium constants 
Species distribution curves represent the percentages (or partial mole fractions) or 
equilibrium concentrations of the different chemical species present in a solution under given 
conditions in a representative manner [20]. Concentration distribution curves are generally 
presented as a function of a single variable, such as pH, where the fixed values of the 
components (reagents) uniquely determine the molar ratios of the species formed. 
The equilibrium concentrations of various species are computed by solving the system 
of mass balance equations constructed for each component (Eqs. 1–3 for a system containing 
three components: M, L, and H), and these mass balance equations are then solved iteratively 
for the concentrations of the free components. In addition, it is necessary to know the 
stoichiometry and overall/cumulative stability constants (MpLqHr of all the associations 
(e.g., ligand species, LHr; metal complexes, MpLqHr; and metal hydrolysis products, MpHr; 
where p, q, and r are the stoichiometric numbers of the components in the given species) and 
the ionization constant of water (Kw).MpLqHr is defined for the general equilibrium 
shown in Eq. 4, where M denotes the metal ion and L is the completely deprotonated ligand. 

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
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rqp
pqriH
iii [H][L][M]βr[H]c       (3) 
pM + qL + rH  MpLqHr as (MpLqHr) = [MpLqHr]/[M]
p[L]q[H]r  (4) 
Various computer programs have been developed to produce distribution diagrams for 
the species formed in solution, such as HYSS [21], Medusa [22], PSEQUAD [23], DISDI 
[24], and BEST [25]. The speciation distribution curves calculated for compounds containing 
dissociable protons represent the fractional contribution of each protonated (LHr) and 
unprotonated (L) species in equilibrium, and thus the average number of protons bound and 
the actual charge of the ligand can be viewed as a function of the pH. As a simple example, a 
single metal-one ligand system species distribution diagram was calculated for the Cu(II) 
complexes formed with GlyGly at a metal-to-ligand ratio of 1:2 and at millimolar 
concentrations based on previously reported data [15], as shown in Fig. 1a. The diagram 
clearly shows that the complexation process starts with the formation of the mono-complex 
[Cu(GlyGly)]+ at pH > 3.2, prior to the deprotonation of amide group, and the complex 
[Cu(GlyGly)H-1]
0 predominates in the neutral pH range. The bis-ligandum complex 
[Cu(GlyGly)2H-1]
– and ternary hydroxido-species ([Cu(GlyGly)2H-2]
2–) also form in the basic 
pH range. In order to represent the effect of the metal-to-ligand ratio on the fate of the 
[CuGlyGlyH-1]
0 complex in solution, speciation curves were computed as a function of the 
total concentration of GlyGly at pH 7.4, as shown in Fig. 1b, which indicates that a quite high 
ligand excess (tenfold) is necessary for the complete formation of [Cu(GlyGly)2H-2]
2–. 
Speciation curves can be computed for ternary (mixed metal or mixed ligand) or 
multicomponent systems with increasing numbers of components. Predominance curves 
calculated for a hypothetical M‒L1‒L2‒H system, where the formation of only binary MpL
1
q 
and MpL
2
q complexes is assumed and the ligands are in equimolar amounts, are advantageous 
for comparing the relative metal ion-binding abilities of ligands in the selected pH range [26]. 
This approach is especially useful when the cumulative stability constants are not directly 
comparable. However, as the numbers of components and associations increase, the situation 
becomes closer to more complex real-world samples such as biofluids (e.g., human blood 
serum) and natural aquatic systems (e.g., surface or ground water). Blood serum contains 20 
essential amino acids (AA), 12 essential metal ions, more than 100 LMM ligands, and 
numerous HMM components (such as proteins) with potential metal ion-binding abilities [27-
29]. To determine the serum (or plasma) speciation of a particular metal ion or metal 
complex, it is necessary to define a series of chemical equilibria that represent the system, 
where knowledge is necessary of the stoichiometry and cumulative stability constants of all 
associations, including the binary and ternary complexes formed with the LMM and HMM 
serum compounds, and the total concentration of the components. Several speciation 
modeling calculations for the distribution of metal ions or metal complexes in human blood 
serum have been discussed in previous reviews [27-30]. The computer program ECCLES [31] 
can be used to predict the speciation of metal ions/complexes (or ligands) in biological fluids 
(see Section 4), although it can only operate with LMM ligands by assuming that the HMM 
components have a weaker impact in controlling the distribution of metal ions due to the 
generally slow interaction kinetics of proteins. However, protein–metal equilibria cannot be 
excluded, especially in faster complexation processes with the proteins. Indeed, protein 
interactions were included in computer simulations of the distributions of Al(III) [32], 
V(IV)O [33], Zn(II) [34], Ga(III) [35], and Gd(III) [36] complexes in serum. In the case of 
speciation in natural/industrial waters, the redox processes, solubility properties, and 
adsorption interactions must also be considered (see Section 4.2). 
 
 
 
 
Fig. 1 Concentration distribution curves for the Cu(II) ‒ GlyGly system: (a) between pH 2 
and 11 (cCu(II) = 1 mM, cGlyGly = 2 mM), and (b) between cGlyGly = 1 mM and 10 mM (cCu(II) = 
1 mM, pH = 7.4). Calculations were performed using the protonation constants of GlyGly and 
the overall stability constants of the Cu(II) complexes (I = 0.2 M KCl, t = 25C) taken from 
Ref. [15]. 
A large number of significant metal–ligand stability constants and associated 
thermodynamic data have been critically evaluated by IUPAC and selected values have been 
recommended. The SC-Database provides access to published stability constants for metal 
complexes of ca. 9800 ligands [37], although data for HMM compounds are limited. 
It should be noted that the thermodynamic equilibrium constants are based on activities 
that depend on temperature and pressure. Most reported stability constants are considered as 
stoichiometric constants, which are expressed as equilibrium concentration quotients, and thus 
they are valid only at a given ionic strength (I) and in a given medium. The activity is 
proportional to concentration, where the proportionality constant is the activity coefficient (γ) 
that brings the stoichiometric constant close to the thermodynamic constant. This is why the 
ionic strength must be kept constant during experimental determinations of stability constants. 
The mean activity coefficient (γ±) of a dissolved electrolyte depends on the ionic strength and 
it can be calculated in diluted solutions according to the Debye–Hückel theory [38], or in high 
ionic strength solutions using the Pitzer interaction model [39]. The thermodynamic constants 
are referred to zero ionic strength, so they can be calculated when the activity coefficients are 
known, or obtained by extrapolating the stoichiometric constants determined at various ionic 
strengths according to the Davies equation [40]. The conditional stability constants introduced 
by Schwarzenbach [41] also consider other equilibria that occur simultaneously with metal–
ligand complex formation such as (de)protonation processes of the ligand and the hydrolysis 
of metal ions. Thus, conditional stability constants are valid only under the given pH value 
and conditions. 
Selecting adequate equilibrium processes and applying reliable stability constants are 
essential for calculating speciation curves. The most problematic issue that affects rigorous 
mathematical modeling calculations of the distribution in a multicomponent systems is the 
lack of suitable stability constants that are relevant to the given conditions (e.g., in the case of 
the human serum: t = 37C, I = 0.10 M NaCl, pH = 7.4). More thermodynamic data are 
increasingly being published and the calculations can be run easily due to advances in 
computer software, but the predicted distributions and transformation processes for metal ions 
or complexes often have limitations. Therefore, computational modeling still cannot replace 
controlled instrumental methods for determining speciation, although it provides a very 
important alternative approach and it can be helpful understanding experimentally obtained 
findings and reduce the experimental effort required. 
 
3.2. Parallel application of speciation and solution structural investigations 
Structural investigations of solutions mainly based on spectroscopic measurements can 
be used to confirm speciation/equilibrium data. These methods are usually required because 
of the limitations of pH-potentiometry and other thermodynamic methods. However, these 
methods measure non-selective effects, e.g., proton liberation, which are insufficiently 
sensitive to detect minor processes/species. Thus, in order to use any spectroscopic method in 
quantitative data evaluations, the concentrations of the individual species formed should be 
calculated from the information obtained. 
For example, pH-potentiometry cannot be used above or below a certain pH value, at a 
low L/M ratio, or when the measureable concentration or pH range is reduced, e.g., because 
of the low solubility of a complex. Furthermore, some complex formation reactions might not 
be pH-sensitive, such as oligomerization processes, which cannot be detected directly by pH-
potentiometry. Excessively high or low stability constants are also problematic because the 
formation equilibrium for these species can only be partially observed or not at all in the 
measurable pH range, so the stability constants cannot be determined with sufficient accuracy 
by pH-potentiometry [14b]. Similar problems may also occur during the evaluation of 
calorimetric, kinetic, or cyclic voltammetric measurements. 
In order to perform joint evaluations of pH and spectral data, the experimental 
conditions should be kept the strictly same, as required with pH-potentiometry (i.e., constant 
I, T, and pH calibration method). The data obtained from different spectroscopic 
measurements can also be combined. Spectroscopic approaches are sometimes used only to 
determine conditional stability constants, such as measurements at a certain pH. 
The advantages of spectroscopic methods may include the more accurate detection of 
minor species and the more appropriate determination of the number of the species formed. 
Even if the spectral bands overlap with each other, such as in UV-visible (UV-Vis) 
spectrophotometry, matrix rank analysis of the whole data set can yield appropriate values for 
a number of colored species [42]. The practical disadvantages of spectroscopic methods 
compared with pH-potentiometry include the lower number of data points collected and less 
accurate measurements of the necessary pH values. 
The speciation determined by spectroscopic methods may be referred to as structural 
speciation, which does not always agree with the thermodynamic speciation. A metal complex 
with a given composition may have more than one structure (isomers such as fac-mer 
isomerism) [43]. In addition, changes in composition do not always lead to changes in the 
spectra. For example, the protonation of a ligand at a non-coordinated moiety located far from 
the coordination sites will not change the observed d-d bands or the electron paramagnetic 
resonance (EPR) spectra of a 3d metal ion [44]. The equilibria of the structural speciation 
(appearance of isomers) sometimes can be described perfectly by microconstants [45,46] 
(together with the formation constants), but an incompletely verifiable assumption is needed 
in most cases, which makes the results questionable. In the following sections, examples 
based on the application of UV-Vis, circular dichroism (CD), nuclear magnetic resonance 
(NMR), and EPR spectroscopy, as well as fluorimetry and mass spectrometry (MS), are 
discussed for obtaining speciation information. More detailed discussions of the spectroscopic 
methods can be found in other papers in this special issue. 
 
3.2.1. UV-Vis, circular dichroism, and fluorescence spectroscopy 
If the absorbance follows the Lambert-Beer law, UV-Vis spectroscopy can be used to 
determine the concentration of each individual species and the data set obtained can be jointly 
evaluated with pH-potentiometric data. However, the data include an extra parameter set 
comprising the molar absorbances (spectra) of all individual species formed. The UV bands 
usually overlap with each other, so it is sometimes impossible to correctly determine the 
molar absorbances of the minor species, where the errors increase with the number of species 
with unknown molar absorbances. CD spectroscopy can be used in a similar manner to UV-
Vis spectroscopy in speciation studies, but only optically active species can be detected. 
Transition metal complex formation can be monitored based on either the d-d bands 
(higher concentrations used), the ligand to metal transfer bands, or the metal to ligand charge 
transfer bands (lower concentration used). The d-d bands are forbidden transitions that result 
in low molar absorbance values, so they are often not  sufficiently sensitive to measure 
complex formation at millimolar or lower concentrations. The charge transfer and ligand 
bands are usually more intense, and the optimal concentration is around 100 times lower. 
The requirement for a CD signal is that an asymmetric center should be near the 
chromophore [47]. The advantage of this method compared with UV-Vis spectroscopy is that 
not each complex formed is CD-active and this technique usually provides more resolved sets 
for both the d-d and CT transition bands than the simple UV-Vis absorption spectra. For 
example, complexes of tri- and dipeptides have been studied extensively using CD 
spectroscopy [48,49]. The correlations between the configuration of the complex and the sign 
and intensity of the CD bands observed in the CD spectra can be understood or interpreted 
using the double octant or hexadecant sector rule [50]. 
Fluorimetry is only applicable to fluorophore ligands and at quite low concentrations, 
where this method is frequently used to determine the pKa values of fluorophore components 
(e.g., see Ref. [51]). The advantage of the method is its selectivity and applicability at more 
biologically relevant low concentrations (c ~10–5 to 10–7 M). It should be noted that the proton 
dissociation constant of a ligand may differ in the excited and ground state in certain cases, 
which may hinder the determination of the ground state pKa value. In metal complexes, the 
effect of dilution on actual speciation is also an important issue because the dissociation of a 
complex is more pronounced at lower concentrations than higher concentrations by several 
orders of magnitude. However, high sensitivity may also be a disadvantage because any type 
of impurity, even from the solvent, can disturb the equilibrium at a low concentration. It is 
quite unusual to use fluorimetry in metal-ligand systems because all the non-fluorescent 
species can absorb the excitation or emitted light. Furthermore, all fluorimeters measure the 
intensity signal in arbitrary units, and thus the spectra measured with different fluorimeters 
are not directly comparable. However, if the bound and unbound ligand have fairly distinct 
fluorescent properties (such as fluorogenic ligands), and the metal complex(es) formed have 
relatively high solution stability, then  fluorimetry is an efficient tool for determining 
formation constants, e.g., for Ga(III)‒8-quinolinol complexes [43]. 
 
3.2.2. Nuclear magnetic resonance spectroscopy 
Many metal ions are paramagnetic, which leads to shorter relaxation times, a wide 
chemical shift range, and broadened NMR signals. Thus, complex formation by some of the 
most frequently studied metal ions (e.g., Fe(II)/(III) and Cu(II)) cannot be studied easily by 
NMR spectroscopy [52]. 
In diamagnetic samples, the equilibrium can have two different profiles. 
(1) If fast exchange processes occur, the NMR spectrum has a single signal, which is averaged 
according to the proportions of the partial mole fractions for the active nuclei found in various 
chemical environments [14c,53]. If the conditions vary, such as the pH or ligand-to-metal 
ratio, then the partial mole fractions and the chemical shift will change. The simplest example 
of this behavior is the protonation equilibrium of an organic ligand, where the chemical 
shift(s) include information about the equilibrium, and the protonation constants of a ligand 
can be calculated based on the pH-dependence of the observed chemical shifts [54]. The 
effect of averaging is also apparent in the reciprocal relaxation times and these data may be 
used to study equilibria where paramagnetic species also participate. 
(2) If slow exchange processes occur, all of the various chemical environments are 
represented by separated signals in the NMR spectra. The integrated intensities of the bands 
are proportional to the (equilibrium) concentrations of the species. The number of complexes 
formed and the stability constants can then be determined easily [14c]. The peak areas include 
information about the equilibrium (it should be noted that a correct pulse sequence is needed 
for NMR measurements if the data are to be used in qualitative evaluations). 
If the exchange rate frequency (Hz) of the chemical environments is comparable to the 
difference in the chemical shift of the individual signals, then case 1 or case 2 cannot be 
clearly observed. 
The most frequently used 1H- or 13C-NMR spectroscopic methods can be employed to follow 
simple protonation processes in organic ligands (the labile protons are usually not observable 
in protic solvents such as water, although peptide protons are generally visible at pH < 5) as 
well as for studying complex formation with metal ions. The exchange rate of complex 
formation depends greatly on the type of metal ion, e.g., only fast equilibria are usually 
observable for Zn(II) upon complexation [55], whereas all the species formed can be detected 
separately if the ligand exchange is sufficiently slow, e.g., Pd(II) complexes [56]. However, 
slow and fast exchanges can appear in the same system, as well as in the same spectrum, and 
in the same species (Fig. 2). In the Ru(II)(η6-p-cymene)]–thioallomaltol system, the ligand 
exchange rate is high between the free ligand and the ligand bound in a monodentate (S) 
manner, but slow between the ligand bound in a monodentate (S) or bidentate (O‒,S) manner 
[57]. 
 
Fig. 2 Part of the low-field regions of 1H NMR spectra recorded for the [Ru(II)(η6-p-
cymene)]–thioallomaltol system at the metal-to-ligand ratios indicated. CH(6) protons of the 
ligand: unbound ligand (), ligand bound via (O‒,S) (), and ligand bound via (S) (). 
Adapted from Ref. [57]. 
Similarly, the presence of slow and fast exchanges can be observed in many cases in the 
51V-NMR spectra of the H+-HVO4
2– system [58,59]. 
 
Table 2 
Periodic table of elements for which the speciation/equilibria were determined based on 
specific nuclei. The numbers represent previous studies that mentioned the NMR-detectable 
nuclei for the given element. Upper number: studies related to speciation; lower number: 
studies related to stability constants/equilibrium constants and/or speciation. The search was 
performed using SciFinder [60]. 
 
 
 
It would be interesting to identify the NMR measurements of nuclei that are used 
frequently to determine speciation or equilibrium/stability constants (see Table 2). Indeed, it 
seems that three different parameters determine these numbers: (1) the commonness of the 
application, (2) the technical difficulties of obtaining NMR measurements for certain nuclei, 
and (3) the overall importance of the element in speciation chemistry. Based on Table 2, the 
metal-ligand equilibria are monitored more frequently based on one of the nuclei of the ligand 
rather than that of the metal ion. The most frequently used nuclei are the classic (1H, 13C) 
organic nuclei, but others (15N, 17O, 31P, and 19F) are also often used to monitor the chemical 
environment of the ligand. The importance and commonness of C, N, and O exceed the 
technical difficulties involved in their determination (low abundance and receptivity). The 
importance is similar for P and S, but because it is easy to measure and interpret the 31P-NMR 
spectra, these are much more common, and the same is true for 19F. 
The most frequently studied metal nuclei are 23Na, 27Al, 29Si, and 51V, but 195Pt, 119Sn, 
113Cd, 183W, 199Hg, and 205Tl are also measured often. If the number of protons in the nuclei is 
an odd number, the natural abundance of the NMR active nuclei is usually much higher than 
that with an even number. It would be interesting to study Ca/Mg as well as Na, but the large 
difference in the natural abundance of the NMR active nuclei leads to their significantly lower 
usage. It is easy to measure 27Al and 51V (only in the oxidation state of V) but their overall 
importance is less significant than that of Fe/Cu, or even Pt/Hg. It should also be mentioned 
that the paramagnetism of transition metal ions also hinders their measurement. 
 
3.2.3. Electron paramagnetic resonance spectroscopy 
EPR spectroscopy is a powerful ion-specific method in some cases. As mentioned 
earlier, most of the common 3d transition metal ions are paramagnetic and they are targets for 
EPR investigations, although the spectra or spectral changes are not always sufficiently 
informative to perform speciation studies based on EPR alone. The most frequently studied 
ions are Cu(II), V(IV)O, Fe(III), and Mn(II) (see Table 3). Cu(II) has been studied most 
frequently due to the same reason given for NMR, i.e., it is easy to measure, the spectra are 
informative, and the overall importance of Cu(II) is high. The detectability of V(IV)O is 
similar to that of Cu(II), but it is much less important. Fe(III) is also important but its spectra 
are less informative in a similar manner to Co(II). There are also unresolved issues, e.g., 
Nb(IV) has easily detectable informative spectra but the 4+ oxidation state is not as common 
for Nb as 5+, and its equilibria are also of less interest. Due to the higher inertness of the 
4d/5d transition metal ions and their complexes, there is no reason to study their speciation by 
spectroscopy. 
Systems that contain odd numbers of electrons (d1: V(IV)O, d3: Cr(III), d5: 
Mn(II)/Fe(III), d7: Co(II), d9: Cu(II)) can usually be measured at room temperature with the 
most common X-band EPR instruments. Measuring the EPR spectra of ions with an even 
number of electrons usually requires a lower temperature and/or higher frequency, so 
equilibrium studies of these systems are rare. 
 
Table 3 
Transition metal components of the periodic table of elements for which the 
speciation/equilibria of the ions were determined by EPR. The numbers represent studies that 
mentioned the element: upper numbers = studies related to speciation, lower numbers = 
studies related to stability constants/equilibrium constants and/or speciation. The search was 
performed using Scifinder [60]. 
  
 Based on the EPR spectral parameters (g, A) of Cu(II) and VO(IV) complexes ([61, 
62]), assumptions can be made regarding the nature of the coordinating donor atoms. The 
anisotropic spectra measured at liquid nitrogen temperature are usually more informative for 
solution structural predictions, but the molar ratios derived from these spectra are not always 
directly comparable with other speciation results measured at room temperature due to the 
shift in temperature. 
The advantage of EPR spectroscopy compared with other techniques (e.g., UV-Vis and 
CD) is that the measured spectra (room temperature, isotropic) can be simulated perfectly 
using only a few parameters (g0, A0, and bandwidths; e.g., , , and  values for Cu(II)). This 
makes the determination of the number of species formed and their identification more 
appropriate and accurate. 
A unique application (2D EPR) [63] can handle mathematical equilibrium data 
(formation constants and log ), conditional data (total concentrations of the components and 
pH), and EPR parameter sets (e.g., g0 and A0 for all species) to simulate all the spectra 
measured at various pH values and different metal-to-ligand ratios. 
 
 
3.2.4. Mass spectrometry 
This very rapidly developing area of analytical chemistry has also influenced speciation 
studies, where it can be used to identify the compositions of the species formed in solution 
[64]. This method is appropriate for application to inert systems, but it is destructive and can 
disrupt any equilibrium or speciation in labile systems. Therefore, it is quite difficult to 
interpret the data if the mass spectra disagree with the findings obtained using other methods. 
The electrospray ionization-mass spectrometry (ESI-MS) method is used widely to identify 
metal complexes present in solution [65], although the spectra can only be trusted for 
qualitative rather than quantitative purposes. 
 
 
3.3. Modeling calculations in biological or environmental systems using stability 
constants and their experimental confirmation 
In real-world systems, numerous species can be present in different proportions, e.g., 
the majority of the metal ions are bound to proteins in biological fluids and only a small 
proportion is bound to LMM compounds, such as AAs, biophosphates, carboxylates, and 
hydroxycarboxylates. Free transition metal aqua ions only exist in extremely low 
concentrations in biological fluids, so they cannot play significant roles in biological 
processes. By contrast, metal ions bound to LMM compounds have key roles in many 
biological processes, such as intestinal and cellular absorption, transport processes, and 
excretion. These are the mobile forms of metal ions. Understanding these processes requires 
accurate knowledge of the equilibria that determine the relative proportions of the LMM and 
protein-bound fractions. Specific experimental techniques are available to separate and 
determine LMM and HMM bound metal ions. Fractionation is a very important aspect of the 
speciation of trace elements, which usually involves coupling an analytical separation 
technique directly to a metal-sensitive detection system. Detailed discussions of chemical 
speciation in various biological fluids and tissues as well as examples of the application of 
various methods for determining the distribution of trace elements in biological systems are 
provided in the “Handbook of Metal Ligand Interactions in Biological Fluids” edited by 
Berthon [66], and in “Chemical Speciation in the Environment” edited by Ure and Davidson 
[67]. However, it is difficult to apply any structure elucidation techniques to explore the 
complete speciation of a metal ion due to the small quantities (usually micrograms) of the 
analyte. By contrast, computer programs developed to deal with multiple chemical equilibria 
can be employed to calculate speciation for laboratory solutions, as well as for conducting 
simulations of naturally occurring mixtures of metal ions and ligands in biological and 
environmental samples. 
These programs are employed increasingly frequently to determine chemical speciation 
in very complex systems and ECCLES is one of the most widely used simulation programs 
[31]. Computer programs require a rich and reliable database of stability data for all the 
metal-ligand interactions that may occur in biological fluids. The most complete database 
available, which is for blood plasma, includes a set of about 10,000 complexes of ca. 10 
essential and toxic metal ions, over 1,000 ligands, and the results for different plasma 
conditions. As an illustration, Table 4 shows the distribution of Cu(II) in plasma according to 
the LMM constituents calculated using the ECCLES program. 
 
Table 4 
Calculated distribution of Cu(II) bound to LMM constituents of human blood plasma (based 
on data in Ref. [31]). 
 
Cu(II) % Cu(II) % 
Cu(His)(Gln) 19 Cu(His)(LysH)+ 4 
Cu(His)2 16 Cu(His)(Gly) 4 
Cu(His)(Thr) 15 Cu(His)(Asn) 4 
Cu(His)(Ser) 8 Cu(His)(Val) 4 
Cu(His)(Ala) 5 Cu(His)(Leu) 4 
 
The weakness of this model calculation approach is the lack of the necessary data. 
Therefore, the stability constants of binary and ternary metal ligand systems need to be 
determined in advance by focusing on the most important and strongest binders, and thus a 
good estimate can be obtained easily and simply. This approach was employed to obtain 
simulations of the serum distribution of various insulin-enhancing V(IV) [33,68,69] and 
Zn(II) complexes (see Section 4.3.1) [70]. In the ideal case, the calculated results can be 
confirmed by separation methods or structure elucidation techniques [70]. 
The experimental confirmation of modeling calculations is important for insulin-
enhancing metal compounds. Detailed speciation and spectroscopic methods have shown that 
under biological conditions, in the case of the V(IV)O containing antidiabetic compounds 
human serum transferrin (Tf) is the main V(IV)O transporter in the serum [33,68,69], whereas 
human serum albumin (HSA) is the main transporters in the case of the Zn(II) complexes 
[34]. Modeling calculations can determine the detailed distributions of metal ions among the 
LMM and HMM components of serum. Various separation techniques such as ultrafiltration 
[70] and capillary zone electrophoresis inductively coupled plasma MS (CZE-ICP-MS) [34] 
have been employed in the fractionation of different LMM and HMM fractions to confirm the 
basic findings of the modeling calculations, e.g., the distribution of Zn(II)–dipic complexes in  
serum systems (0.1 mM, serum diluted with buffer: 1:4, 24 h incubation at 25C), where most 
of the Zn(II) was bound to HSA, although a minor amount of Zn(II) was bound to dipic, 
whereas no Zn(II) was bound to Tf (Fig. 3). 
 
 
Fig. 3 Electropherogram of [Zn(dipic)2]
2‒ after incubation for 24 h with blood serum diluted 1:4 with 
incubation carbonate buffer. Traces are shown for 64Zn and 34S (for HSA and Tf detection). Peak 
identification: 1 = Tf; 2 = HSA adduct and 3 = [Zn(dipic)2]
2–.(dipic: 2,6-dipicolinic acid, 
c([Zn(ligand)2]) = 100 μM, pH = 7.40; T = 25°C). Adapted from Ref. [34] 
 
 
Environmental samples can be just as complicated as biological samples. Mercury is 
usually present in natural waters at trace or ultra-trace levels, which presents a formidable 
challenge to even the most up-to-date sampling, sample handling, and analytical procedures 
for determining mercury in environmental samples. 
The major inorganic and methyl mercury species in seawater and fresh water 
environments have interesting distributions. Calculations predict that divalent mercury, 
Hg(II), should exist predominantly as chlorido complexes in sea water, but the major 
chemical forms of mercury in fresh water systems are chlorido, hydroxido, and mixed species. 
The relative proportions of the latter species depend greatly upon the pH of the medium. 
However, the validity of computational methods for determining the speciation of mercury 
needs to be tested based on reliable data obtained using one or more experimental methods 
[71]. 
Current methods only allow the classification of several common mercury species into 
operationally defined categories according to specific physical or chemical properties. A 
suitable analytical method (Fig. 4) is a variation of the classification scheme described by 
Lindqvist and Rodhe [72], where parts of this procedure have been applied to analyze 
mercury in environmental samples. However, very few published results have been obtained 
using the entire scheme. The initial separation into particulate and dissolved forms of mercury 
is usually affected by filtration (filter medium with a pore size of 0.45 m). Volatile species 
such as elemental mercury and dimethyl mercury can be readily separated from nonvolatile 
forms (e.g., HgCl2, Hg(OH)2, and CH3HgCl) by gas stripping (“purge and trap”) techniques. 
Differentiating “reactive” and “non-reactive” species is usually accomplished in one of two 
ways: either “reactive” forms are reduced to elemental mercury by stannous chloride (in acid 
solution) or “non-reactive” compounds are reduced (to Hg(0)) by NaBH4; or “nonreactive” 
forms are converted into “reactive” forms by treatment with concentrated HNO3. In this 
scheme, mercuric halides, HgX2, mercuric hydroxide, Hg(OH)2, and Hg(II) complexes with 
organic acids are treated as “reactive” forms, whereas the “non-reactive” forms include 
monomethyl mercury species, CH3HgX, mercuric sulfide, HgS, and sulfur-containing 
organomercury complexes [71]. The results obtained by this experimental separation of 
various mercury species can be compared with the results of fractionation calculations. 
 
 
Fig. 4 Classification scheme for Hg species in natural waters. (Based on Ref. [66].) 
 
 
4. Examples of the applications of speciation: analysis and 
modeling calculations  
4.1. Chemical speciation in trace analytical and environmental chemistry 
Previously, most trace analytical measurements focused on the total amount of a 
specific element (such as toxic elements, including arsenic, mercury, or cadmium, and 
elements that are necessary for living organisms, including selenium and magnesium), 
because most atomic analysis techniques are destructive. At present, it is generally accepted 
that the biological availability, toxicity, cellular uptake, and trafficking of metal ions/metal 
complexes depend greatly on their actual chemical and physical forms, oxidation state, etc., 
and not merely on their concentrations [73]. For example, the LD50 values (rat) of inorganic 
arsenic species are between 3–20 mg/kg, but higher than 10000 mg/kg for organic compounds 
such as arsenobetaine [74]. Chemical speciation studies must be performed to obtain more 
reliable information about any sample. In order to determine the specific forms/species of an 
element, they must first be separated before reaching a destructive detector [73]. In general, 
the appearance of multiple forms is described by speciation, whereas the process employed 
for obtaining quantitative estimates of the contents of different species is called speciation 
analysis [74]. 
The levels of speciation considered by trace analytical chemistry are as follows [74]. 
i) Screening speciation: Search and determination of selected chemical species. 
ii) Group speciation: Search and determination of groups or classes of selected species. 
iii) Distribution speciation: Search and determination of selected chemical individual types 
of particular elements in analyzed samples. 
iv) Individual speciation: Search and determination of all chemical individual types present 
in a sample. 
 
Table 5 
Application areas for speciation trace analysis [74] 
Element  Application area for speciation analysis 
Aluminum  Al  Aggregates [75]  
Antimony  Sb  Redox forms and organoantimony compounds in the environment 
[76,77] 
Arsenic  As  Redox forms and organoarsenic compounds in the environment [77] 
Arsenic in food products [78] 
Forms of arsine in air [79] 
Cadmium  Cd  Cadmium in food products [80] 
Chromium  Cr  Redox forms of chromium, Cr(VI) in the environment [81,82] 
Lead   Pb  Forms of lead compounds in the environment [83] 
Mercury  Hg  Forms of mercury compounds in the environment [84-86] 
Selenium  Se Inorganic and organometallic selenium compounds in the 
environment [87] 
Thallium Tl Thallium compounds in river water [88] 
Tellurium Te Tellurium compounds in the environment [89] 
Uranium U  Forms of uranium compounds in seawater [90] 
Zinc  Zn Forms of zinc compounds in the environment and food [91] 
 
The usual analytical procedure comprises filtration (to obtain the soluble and insoluble 
fractions), separation from the matrix and fractionation (e.g., by high-performance liquid 
chromatography (HPLC), size exclusion chromatography (SEC), gel permeation 
chromatography, anion/cation exchange chromatography, CZE, ultrafiltration, dialysis or gas 
chromatography in the case of volatile species). The isolated species are then determined by 
atomic absorption spectrometry, flame atomic absorption spectrometry, ICP-optical emission 
spectrometry, ICP-MS, MS, fluorimetry, atomic fluorescence spectrometry, UV-Vis, or 
electrochemical methods depending on the type of analyte [74]. 
Chemical speciation is also essential for many environmental problems, but the direct 
instrumental determination of metal ion/complex distributions in biological and 
environmental samples has several difficulties: i) the identification and selective 
determination of different species are challenging due to the lack of adequate reference 
materials, ii) the technique employed can disturb and shift the chemical equilibria, and iii) few 
methods are appropriate for the detection of species present at ultra-trace levels. In addition, 
speciation analysis is fairly difficult in complex matrices such as sediments, soils, aerosols, 
and fly ash. 
Numerous previous reviews [92-98] and book chapters [99-102] have summarized the 
most important procedures and findings related to speciation determination for different 
essential and toxic metal ions in a wide variety of environmental samples. The speciation of 
metallic (and some non-metallic) compounds that cause human health risks was reviewed in 
detail by the WHO Environmental Health Criteria Program [103]. Assessments of the most 
significant examples are considered in the present review for elements related to acute toxicity 
(e.g., Cr, Ni, As, Hg, and Ba), carcinogenicity (e.g., Cr, Ni, and As), lung toxicity (Co), 
nephrotoxicity (Cd), reproductive toxicity (Ni and Hg), and neurotoxicity (e.g., Mn, Hg, Pb, 
and Sn) in order to determine the relationship between exposure to environmental pollutants 
and human health. Reviews have described the speciation of Hg compounds in environmental 
and biological samples [92,93], Al [94], organolead [95], As [96], Cr in ground water [97], 
and radionuclides [98]. 
Due to the complexity of real-world systems and the limitations of analytical methods, 
speciation determination usually relies on analytical techniques combined with mathematical 
modeling calculations. In speciation calculations, sorting the most feasible interactions and 
associations present in solutions as well as selecting their stability constants from published 
data can significantly affect the final predicted distribution. Several computer programs have 
been developed and employed to calculate the concentrations of various chemical species at 
equilibrium based on a database of equilibrium stability constants for inorganic species 
encountered in water [104]. In addition to the formation of different metal-ligand complexes, 
the equilibria between soluble and insoluble phases, as well as the adsorption of colloids must 
be considered during computational modeling. One problem is that most of the stability data 
in databases were obtained for metal-ligand species at 25C [37,105]. However, determining 
thermodynamic data for the complex formation processes involving the macromolecules or 
colloids present in natural systems, such as humic and fulvic compounds, polysaccharides and 
clays, also causes difficulties related to the structural and physicochemical complexity of 
these complex-forming agents. The most important databases containing experimental results 
for speciation constants are SC-Database (IUPAC) [37], the National Institute of Standards 
and Technology standard reference [106], and Joint Expert Speciation System thermodynamic 
database [107]. The most frequently used programs are JESS [108], MINEQL [109], and 
MINTEQA2 [110]. These programs contain built-in databases for many chemical equilibria, 
including complexation, precipitation, dissolution, adsorption and redox reactions. Some also 
include Debye-Hückel or specific interaction theory parameters for ionic strength correction. 
Several programs can handle slow reaction kinetics for processes such as 
adsorption/desorption or precipitation/dissolution. 
 
4.2. Chemical speciation of Al(III) and Fe(III) in water and biology 
With the exception of alkaline and some alkaline earth metals, the metal ions in 
biological systems bind to different LMM or HMM biomolecules during their absorption, 
transport in biological fluids, and distribution among different organs and excretion processes. 
The presence of these biomolecules may significantly alter the properties of metal ions in 
solution. The general solution states of two metal ions, i.e., the essential Fe(III) and toxic 
Al(III), are considered in pure aqueous solution and biological systems in the following, 
where their serum transport properties are also presented to explain how the biological milieu 
affects the solution state/speciation. 
 
4.2.1. Hydrolysis of toxic and essential metal ions: Al(III) and Fe(III) 
All equilibrium studies of metal ion-ligand systems in aqueous solution with either 
essential or toxic metal ions require a speciation model and adequate stability data for the 
metal ion–OH– system because the ligand must compete with the OH– ion for the metal ion to 
form complexes. This fact has stimulated much research in this field, including the well-
known book by Baes and Mesmer [2]. In the following, the results obtained for the hydrolysis 
of the toxic Al(III) [3] and the essential Fe(III) ion [6] are considered briefly. The speciation 
of both systems is complex because of the time- and concentration-dependent formation of 
oligonuclear hydrolytic species. 
[Al(OH)]2+ is a well-defined species with a pK of ~5.5. At a more acidic pH, only 
[Al(H2O)6]
3+ exists, whereas only [Al(OH)4]
‒ exists in the basic pH range. Between the two 
extremes, the species present in a slightly acidic to neutral solution are less well defined 
because soluble polynuclear complexes may also be formed in addition to the solid compound 
Al(OH)3. This problem is due to the very slow conversion of oligonuclear hydroxido species 
to larger polynuclear complexes, which are necessary precursors of the macromolecular 
polymer Al(OH)3. It may take hours or even up to a day to reach thermodynamic equilibrium, 
which means that soluble hydroxido complexes can be maintained almost indefinitely in a 
metastable state under conditions where the solid Al(OH)3 is the thermodynamically stable 
species. The analytical (total) concentration of Al(III) greatly affects speciation [2]. The 
formation of a highly polymeric species [Al12(OH)32]
7+ was demonstrated unambiguously in 
the solid state by X-ray diffraction, as well as in solution by 27Al and 17O NMR [111]. 
Moreover, the most probable oligomeric species formed in solution are the dimeric 
[Al2(OH)2]
4+ and trimeric [Al3(OH)4]
5+. An important question concerning the speciation of 
Al(III) in practical systems is the lowest concentration of Al(III) where the formation of 
polynuclear species must be considered. Their formation is certainly negligible in biological 
fluids or tissues, where the concentration of Al(III) can only reach the µM level, but in 
toxicological studies or environmental samples, various soluble Al(III) species are present in 
mM concentrations that are not negligible [2]. 
The hydrolysis of ferric ion-containing solutions is readily induced by dilution or 
adding a base, where these hydrolytic reactions involve simple deprotonation and more 
complex oligomerization reactions [112-116]. Initially, at a rather acidic pH, the purple aqua 
ion [Fe(H2O)6]
3+ liberates one proton ([Fe(OH)]2+), which is followed by dimerization 
([Fe2(OH)2]
4+) to yield a yellow solution. The equilibria leading to mono- and dinuclear 
complexes such as [Fe(OH)]2+, [Fe(OH)2]
+, and [Fe2(OH)2]
4+ are formed rapidly [117]. The 
low molecular hydroxido complexes interact to produce species with higher nuclearity (e.g., 
[Fe3(OH)4]
5+). These polynuclear complexes can be isolated as amorphous species. They 
comprise iron cores of nuclearity (p) with OH– and O2– in bridging positions, and they can be 
represented by the general formula: FepOr(OH)s
3p–(2r+s). The charged polyelectrolytes can be 
coagulated under specific conditions or simply by ageing [118]. The coagulation processes 
can be influenced greatly by various biomolecules, such as proteins, carbohydrates, and lipids, 
where this process is called biomineralization and it may lead the formation of the ferrihydrite 
core of ferritin. 
 
4.2.2. Role of human blood serum in transport and distribution processes 
Serum is the liquid portion of blood obtained after coagulation, excluding the red and 
white blood cells, which contains all the plasma proteins such as HSA, Tf, globulins, 
fibrinogen, and other specific proteins and molecules. From a speciation viewpoint, the serum 
constituents can be classified into two distinct groups, i.e., the LMM and HMM serum 
constituents, where the latter mostly comprise peptides and proteins. 
The interactions between metal complexes and serum proteins such as HSA and Tf can 
have profound effects on absorption, distribution, metabolism, and excretion properties, and 
toxicity. In addition, the binding of a drug to these transfer proteins may affect targeted 
delivery, thereby increasing selectivity and decreasing the adverse effects. For example, 
binding to Tf can be advantageous for the cellular uptake of antitumor drugs via 
overexpressed Tf-receptors due to the higher iron demand of cancer cells, while the 
accumulation of HSA adducts is possible in inflamed tissues and tumors due to enhanced 
permeability and a retention effect. 
HSA is the most abundant protein in human blood plasma, where it comprises about 
half of the serum protein content, with a typical concentration of 530–750 M [119]. HSA 
maintains oncotic pressure, buffers pH, and transports thyroid and other mostly fat-soluble 
hormones, fatty acids, and unconjugated bilirubin, as well as many drugs. The serum albumin 
levels can affect the half-lifes of drugs [120]. HSA greatly augments the transport capacity of 
serum due to its high concentration and extraordinary binding capacity [121]. HSA has 
nonspecific binding pockets that can bind chemically diverse endogenous and exogenous 
compounds, where the principal sites are located in subdomains IIA, IIIA, and IB, which are 
often called sites I, II, and III, respectively [122]. 
Four types of metal ion-binding sites have been described: [123] the N-terminal binding 
site specific primary binds Cu(II) and Ni(II) (“ATCUN” = amino terminal Cu(II) and Ni(II)) 
[119,123]; the multi-metal binding site, which primarily binds Zn(II) and other bivalent metal 
ions [124]; site B is the primary binding site for Cd(II) but can also bind Zn(II) [123,125]; and 
the reduced thiol of Cys-34 binds gold and platinum compounds [123]. 
Transferrins are iron-binding blood plasma glycoproteins that control the level of free 
Fe(III) in biological fluids [126]. Tf comprises a polypeptide chain containing 679 AAs and 
two carbohydrate chains, with alpha helices and beta sheets that form two domains. The N- 
and C- terminal sequences are represented by globular lobes [127]. Tf contains two specific 
but remarkably similar high-affinity Fe(III) binding sites. Each lobe of Tf contains a distorted 
octahedral Fe(III)-binding site containing two Tyr, one His, one Asp, and one bidentate 
carbonate anion (the so-called “synergistic anion”) [128]. Tf undergoes a conformational 
change when saturated by metal ions, where the C- and N-terminal parts move closer to each 
other and assume a closed conformation [5]. The serum concentration of Tf is ca. 37 µM and 
the saturation of Tf with Fe(III) is 15–50% [129], while it also binds efficiently to other metal 
ions such as Ga(III), Zn(II), V(III, IV, V), Al(III), Ru(III), and Bi(III) [130]. 
Immunoglobulins (Igs) are glycoproteins with the ability to react as part of the immune 
response to foreign bodies that are introduced or inoculated into an organism. Igs are divided 
into classes IgA, IgD, IgE, IgG, and IgM, which differ in terms of their biological properties, 
functional locations, and ability to react with different antigens. IgG is the most abundant 
class in the blood and it represents 75% of the total Igs. The IgG concentration in human 
blood serum is approximately 73 M [131]. 
Alpha-2-macroglobulin (2M) is one of the largest plasma proteins. In biological 
systems, it occurs mostly in a tetrameric form and its main function is the inhibition of 
proteases. A CysGlu fraction of the protein seems to play an active role in enzyme inhibition. 
However, the concentration of 2M is rather low in human serum, and thus its ability to bind 
metals is weak. With the exception of Zn(II), 2M has no role in metal ion transport in the 
serum [132]. 
 
4.2.3. Serum speciation by Al(III) and Fe(III) ions 
Absorbed Al(III) is transported by the blood stream but its speciation in blood serum is 
still poorly understood. Most of the Al(III) is bound by the HMM iron transport protein Tf, 
and HSA and other potential HMM carrier serum proteins bind weakly to compete for a 
significant amount of Al(III) [133]. Only citrate and phosphate are efficient binders among 
the LMM binders of serum. The somewhat contradictory speciation models are explained by 
the lack of reliable stability data for the complexes involved in the models and differences in 
the experimental conditions considered for speciation and modeling. 
Harris et al. [134] used different UV spectroscopy, pH-potentiometry, and ESI-MS 
measurements to develop a model at an Al(III) concentration of ~10 µM, which is similar to 
the normal biologically relevant serum level (~0.1–0.3 µM) [135]. The speciation model 
provided in Table 6 of Ref. [32] suggests that 93% of the total Al(III) is bound to Tf. Among 
the pool of LMM aluminum, 88% of Al(III) will be bound to citrate, 8% to hydroxide, and 
~2% to phosphate. 
 
Table 6.  
Speciation of Al(III) at pH ~7.4 and 25°C (based on data in Refs. [134, 136]). 
 
 % of Al(III) bound 
 cAl(III) = 10 M  cAl(III) = 1 mM  
HMM components   
albumin ‒ ‒ 
transferrin 93 77 
LMM components   
phosphate 0.1 14 
citrate 6 5 
citrate-phosphate 2.8 4 
 
 
In mM total Al(III) concentrations, which correspond better to aluminum overload 
conditions and those when the thermodynamic equilibrium is reached (monitored by 
multinuclear NMR; see later), the amount of phosphate-bound Al(III) increases significantly 
and ternary Al(III)-citrate-phosphate complexes can also be detected (see Table 6) [32]. 
The serum speciation of Fe(III) is simpler because it binds almost exclusively to Tf 
[66]. In healthy conditions, the LMM components have negligible importance. Citrate might 
be the only binder of Fe(III), which may be important [116]. The importance of Fe(III)-citrate 
in the serum may increase in iron overload conditions.  
 
4.3. Chemical speciation in medicine 
This section considers several examples of how the endogenous ligands present in 
various biological fluids and tissues influence the species distributions of biologically active 
medical drugs/prodrugs during absorption, distribution, metabolism, and excretion processes 
in the body. 
 
4.3.1. Biospeciation of antidiabetic vanadium(IV, V) and zinc(II) complexes 
Diabetes mellitus (DM), commonly known as diabetes, comprises a group of metabolic 
diseases where high blood sugar levels occur over a prolonged period. Diabetes is due to 
either the pancreas not producing sufficient insulin (type 1) or the cells in the body not 
responding correctly to the insulin produced (type 2). In 2015, it was estimated that 415 
million people had diabetes worldwide [137], where type 2 DM (insulin resistance) comprised 
about 90% of the cases [138]. Type 1 diabetes can be treated with insulin, a natural peptide 
(protein) hormone made of 51 AAs, and over 40% of patients with type 2 diabetes require 
insulin injections as part of their treatment. However, insulin cannot be taken orally because it 
is degraded into fragments in the gastrointestinal tract (GI) so insulin is given as an injection 
in most cases [139]. Thus, this painful treatment needs to be replaced with an insulin 
“mimicker” that can be taken orally. 
Surprisingly, many metal ions have insulin-like effects, such as Cr(III), Mn(II), Mo(VI), 
Se(V), V(IV/V), W(VI), and Zn(II). In particular, vanadium is one of the most efficient [140] 
and zinc is also biologically active at a higher dose by an order of magnitude [140, 141]. 
When it was originally discovered [142], NaVO3 was shown to be toxic but many V(IV)O or 
even V(V)O2 complexes have similar effects without toxicity [143]. Thus, it may be possible 
to improve the insulin mimetic/enhancing effect of vanadium salts using specific complexing 
agents. The orally administered vanadium complex should first enter the GI tract and pass into 
the blood serum, before arriving at the targeted cells. Biotransformation is possible 
throughout this process and the absorption efficacy from the GI tract can be improved by 
formulating the drug in an appropriate manner, including encapsulation [144]. However, the 
original carrier ligand can be replaced by serum/plasma components or endogenous binding 
molecules. The goal of modeling calculations for V(IV)O/V(V) and Zn(II) complexes in 
serum is to explore the potential biotransformation processes. 
The V(IV)O [145-151], V(V) [152,153], and Zn(II) [154] complexes of drug candidate 
ligands and LMM serum constituents have been studied using several methods in a wide 
range of conditions, e.g., by pH-potentiometry in the pH range of 2–11, and complete 
speciation distributions of these multicomponent systems have been reported. 
 
 
Fig. 5 Chemical structures, names, and abbreviations of several drug candidate ligands (in 
their neutral forms). All can form complexes with the composition V(IV)OL2. 
 
HMM serum protein speciation studies have focused on physiological pH conditions 
(7.4–7.5) and only conditional stability constants were obtained. Three of the HMM serum 
components, i.e., apotransferrin (apoTf), HSA, and Igs, have been studied using different 
methods (see Sections 4.3.1.1–4.3.1.2). 
 
4.3.1.1. Interactions of V(IV)O and V(V) with transferrin 
V(V)O binds at the two iron-binding sites and similar to Fe(III), only in the presence of 
HCO3
−. However, the X-band EPR of V(IV)O–apoTf complexes indicates that there are two 
different (A and B) coordination environments for V(IV)O at physiological pH, and these 
differences have been described previously [68]. The stability constants of the V(IV)O-apoTf 
complexes are sufficiently high but they cannot be determined directly at physiological pH 
because the complex formation is actually complete (100%). The free V(IV)O is hydrolyzed 
at pH 7.4 and the composition and stability of the hydroxido complexes formed are not known 
fully, so metal ion competition is not suitable option for accurate determination. Thus, the 
ligand competition method is the only option for obtaining the binding constants. Similar 
conditional stability constants (log 1 = 13.0–13.4 and log 2 = 25.2–25.5) [33, 155] were 
determined by two different groups using four different competitive ligands: nitrilotriacetic 
acid (nta), dhp/mal, and acac, and with various measurement techniques (UV-Vis, CD, and 
EPR spectroscopy). dhp, mal, and acac are drug candidate ligands. Ternary complex 
formation by dhp/mal makes their quantitative description more difficult, where both lobes of 
apoTf can bind a V(IV)O(mal) or V(IV)O(dhp) unit and the coordination environment is 
probably uniform. The almost significant difference between the calculated log K1 and log K2 
values (based on statistical considerations, logK1–log K2 = log (K1/K2) must be 0.6 if the two 
binding positions are equal; see Ref. 8) is in agreement with the spectroscopic observations. 
Mal forms less stable ternary species than dhp and similarly, V(IV)O(mal)2 is less stable than 
V(IV)O(dhp)2. Formation of the ternary complex with dhp is noncompetitive according to the 
concentration of HCO3
−, where in the absence of the synergistic anion (HCO3
−), ternary 
complex formation with dhp is less favored. In fact, a quaternary species has been found: 
V(IV)O – apoTf – HCO3
− – dhp. Thus, the determined stability constants are valid only at pH 
7.5 and a HCO3
− concentration of 25 mM [33] (another ternary complex with dhp has also 
been assigned with a different 1:1:2 V(IV)O-Tf-dhp composition [69]). Ternary complex 
formation was observed with picolinic acid (another drug candidate ligand) lactate (serum 
constituent) and picolinic acid is considered to behave as a synergistic anion [69]. 
The conditional stability constants of the V(V)-apoTf complexes (log 1 = 6.0 and log 
2 = 11.4) were determined by 
51V-NMR spectroscopy and ultrafiltration, and no competition 
was found between V(V) and HCO3
− for the anion-binding positions of apoTf [152]. 
 
4.3.1.2. Interaction of V(IV)O with human serum albumin 
HSA can bind V(IV)O at two independent and different binding sites at least. CD 
spectroscopic studies indicate that vanadium binds (at least partly) as a monomer at the 
ATCUN site and as an EPR silent dinuclear species at the multi-metal binding site. CD 
spectroscopic measurements have confirmed these EPR findings. The stability constants for 
(V(IV)O)HSA (log  = 9.1) and (V(IV)O)2HSA (log  = 20.6–20.9) species were determined 
in liquid nitrogen temperature and room temperature EPR experiments by two different 
research groups [156, 157]. Ternary complex formation (HSA(V(IV)O2(L2)n) with several 
carrier ligands (dhp, maltol, hpno, pic) has been described quantitatively. In these bis-ligand 
complexes the metal ion is coordinated via a surface His side-chain of the protein, which 
binds in the equatorial position to the cis form (with the coordinated water cis to the oxido-O 
atom) of the bis ligand V(IV)O complexes [69]. In the case of the VO(acac)2 complex, no 
ternary complex formation is observed with HSA. The stability constant of cis-
V(IV)O(dhp)2HSA is log K = 25.9 [155]. 
The complexation strength of IgG to VO(IV) is about the same as that of HSA (log  = 
10.3 [158]), where it can also bind and carry bis-complexes such as V(IV)O(pic)2. 
 
4.3.1.3. Speciation of VO(IV) in blood serum 
 
Fig. 6 Speciation of various potentially antidiabetic VO(IV) compounds (10 M) in serum at 
pH 7.4. The summed concentrations of similar species types are depicted: VOA2: VO(IV) 
bound in the binary bis complex, (VO)xBy: binary species formed with the LMM components 
of the serum, (VO)xByCz: ternary species of the LMM components of the serum, (VO)xAyBz: 
ternary species of an antidiabetic complex with LMM components of the serum, (VO)xapoTf: 
binary species of VO(IV) with apoTf, (VO)xAyapoTf: ternary species of an antidiabetic 
complex with apoTf, (VO)xHSA: binary species of VO(IV) formed with HSA, and 
(VO)xAyHSA: ternary species of an antidiabetic complex with HSA. A: carrier ligands, pic, 
mal, and dhp; B and C: LMM components of the serum: citric acid, lactic acid, and 
phosphate. Taken from Ref. [159]. 
 
The speciation of the metal ion among the LMM and HMM components of blood 
serum, and the original metal ion carrier ligands, including mixed ligand species, was 
calculated based on the stability constants and concentration data, and the results are 
summarized in Fig. 6. The results show clearly that: (i) Tf, one of the two important HMM 
binders, is much more efficient than HSA and it can displace 30–70% of the original carrier 
from the complex, or form ternary complexes with them; (ii) only the hydroxypyridinone 
derivative dhp is a sufficiently strong carrier to preserve a significant proportion of the 
VO(IV) in the original complex (in the free form or bound to Tf), whereas in other cases, the 
carrier ligands are displaced by serum components; (iii) among the LMM binders, citrate is 
the only “active” component that can influence the solution state of these antidiabetics. These 
results have been confirmed by native blood serum measurements obtained using 
ultrafiltration, followed by separation through a 10-kDa membrane, where the LMM and 
HMM fraction-bound VO(IV) levels were measured by atomic absorption spectrometry 
[33,160]. Similarly, the protein-bound VO(IV) was separated by anion exchange 
chromatography and determined by ICP-MS. Only Tf can bind V(IV)O and the binding 
ability of the other serum protein (HSA) is negligible [33]. Thus, the most important role of 
the carrier ligand seems to be facilitating the absorption of VO(IV) from the GI tract, but the 
complexes finally fall apart in the serum. Pharmacokinetic investigations [161] have 
supported these predictions using labeled [bis(maltolato)oxovanadium(IV)] complexes. 
However, it should be mentioned that higher concentrations of the V(IV)O complexes, 
e.g., mM level, which may exceed the concentration of the strongest V(IV)O binder protein 
Tf, mean that HSA can also be an important binder of V(IV)O species due to its significantly 
higher concentration in serum [159]. 
Clearly, all thermodynamic models have their limitations because there are actually no 
static equilibria in living systems. Furthermore, it would be difficult to perform calculations 
for the whole blood, such as including the cells in the plasma. However, X-ray absorption 
near edge structure (XANES) studies [162] suggest that red blood cells also have an important 
role in the biospeciation of vanadium. 
 
4.3.2. Speciation of V(V) in blood serum 
 
 
Fig. 7 Calculated speciation of [VO2(hpno)2]
– in blood serum. Taken from Ref. [152] 
 
Among the various drug candidate ligands, hpno forms the most stable complex with 
V(V) at pH 7.4. The conditional stability constant (log β) values for maltol and dhp 
complexes under the same conditions are ~0.6 units lower. 
The stability constants determined by 51V-NMR spectroscopy and ultrafiltration for the 
V(V)-apoTf interaction are in very good agreement. The predicted speciation of 
[VO2(hpno)2]
– is depicted in Fig. 7, which shows clearly that at biologically relevant 
concentrations, i.e., c(V(V)) < 1  10–5M, Tf is the only V(V) binder in the blood serum. 
Under these concentration conditions, the carrier ligands, HSA, or small biomolecules present 
in the serum (lactate, citrate, phosphate, Gly, or His) do not form sufficiently strong 
complexes to compete with apoTf, although ~5% of the V(V) exists as free H2VO4
– ions in 
solution [152]. 
The dipicolinate complex of vanadate has also been studied extensively [163], where 
specific studies have been performed with monolayers and reverse micelles [164], 
unfortunately it mostly decomposes in the serum at pH 7.4 [165]. 
 
4.3.3. Speciation of Zn(II) in blood serum 
Zinc(II) is not as efficient as vanadium at insulin mimesis, but it is an essential element 
and it may be accepted more easily as a medical drug. Studies have been performed with 
some zinc(II) complexes that exhibit insulin-like activities at concentrations of ca. 100 M 
level [159]. The potential interactions of drug candidate complexes in the serum with LMM 
components have been studied in detail by pH-potentiometry [34, 70] based on modeling 
calculations of these binders (without the HMM components) with His and Cys, and their 
ternary complexes as primary Zn(II) binders. 
HSA binds Zn(II) with conditional binding constants in the range of log K = 7.1–7.9 
[166, 167]. 2M also has considerable Zn(II) binding properties, but it is present at a much 
lower concentration in the blood serum than albumin (2–6 M), with conditional formation 
constants of log K1 = 7.49 and log K2 = 5.12 [168-171]. The third possible Zn(II) binder is 
Tf, where the Zn(II) binding constants are log K1 = 7.8 and log K2 = 6.4 (15 mM NaHCO3) 
[172,173] 
If both the HMM and the LMM serum binders are considered together, then modeling 
calculations indicate that most of the total serum Zn(II) is bound to the serum proteins 
(~98%), where HSA is the primary binder (80–90%) [29,34,169,173] followed by 2M (5–
15%) [169-171]. However, the role of apoTf is still under discussion [170,173] and it has 
been reported that a minority of Zn(II) circulates unbound or attached to LMM components in 
blood serum. 
Human serum samples have been incubated with Zn(II) compounds to study the binding 
behavior of Zn(II) complexes with serum components under more realistic conditions. CZE 
experiments with ICP-MS detection were used to identify the metal ion in different serum 
components, which showed that most of the Zn(II) was bound to HSA (~80–95%) according 
to the 34S trace. A minor amount (<5%) of Zn(II) was still coordinated with the original 
carrier (or other buffer components), but no Zn(II) was bound by Tf [34]. Thus, the results of 
modeling calculations (see above) were confirmed experimentally by CZE-ICP-MS and by 
ultrafiltration-ICP-atomic emission spectroscopy [70] studies. 
 
4.4. Biospeciation of anticancer metal complexes in blood serum 
Most of the antitumor metal complexes are administered intravenously, such as Pt(II)-
containing drugs (cisplatin, carboplatin, and oxaliplatin) or clinically investigated Ru(III) 
compounds (vide infra), and serum proteins are the first and most important available 
biological binding partners when they enter the bloodstream. 
Based on their enhanced permeability and retention due to the accumulation of HSA in 
tumor tissues, Pt(IV) prodrugs were designed to bind non-covalently to native HSA by 
Lippard et al. [174], and thus the controlled release of these compounds is possible in disease 
areas [175,176]. Maleimide-functionalized compounds have also been developed (including 
Pt(IV) complexes [177]) that can bind covalently to the free thiol group of HSA (Cys34), 
although a cleavable specific bond between the drug and maleimide moieties is beneficial in 
these cases, e.g., an acidic environment sensitive linker [176]. Fairly diverse binding events 
are possible in terms of the serum protein-binding modes and reaction rates in the case of 
metallodrugs. Binding via non-covalent bonds (such as hydrogen and salt-bridge bonding, - 
stacking interactions, and Van der Waals force) does not change the coordination mode and 
thus the complex retains its original entity. It can be concluded that non-covalent and weak to 
moderately strong reversible binding to HSA might be advantageous for targeted delivery. By 
contrast, irreversible and strong binding, which generally occurs via coordinative bonds 
accompanied by partial or complete displacement of the original ligand(s) by the donor atoms 
of the protein, may lead to the inactivation of metal complexes, especially in slow ligand-
exchange processes. Thus, the complex cannot reach the desired site of action and the 
formation of covalent metallodrug-protein adducts might be responsible for side effects in 
chemotherapy. 
Therefore, obtaining deeper insights into the rate, strength, and the nature of the binding 
between a metallodrug and serum proteins is crucial for understanding their pharmacokinetic 
properties, transport, and mechanisms of action. In order to characterize the reaction rates of 
metallodrug-protein interactions, the formation constants as well as the number and 
localization of the binding sites are available based on a wide variety of conventional and 
advanced analytical techniques [178]. An advantage of spectroscopic methods, such as NMR, 
fluorescence, UV-Vis, CD, X-ray absorption, XANES, EPR, electron nuclear double 
resonance (ENDOR), is that these are non-invasive techniques and the chemical equilibrium 
is not shifted by their application, so they are highly recommended for determining binding 
constants. Various MS methods can be combined with fragmentation experiments to probe 
binding and obtain information about the stoichiometry of protein adducts as well as their 
binding sites. Separation techniques such as ultrafiltration and capillary electrophoresis, 
HPLC, size exclusion chromatography-MS, and ICP-MS have been used widely to study the 
distribution between free and protein-bound forms, or between different blood compartments 
[178,179]. These separation methods are appropriate for investigating the distributions in 
biological fluids and tissues, as well as using serum samples obtained from treated cancer 
patients or animal models. 
The role of LMM compounds in the serum is not negligible because they may be 
responsible for the (partial) displacement of the original ligand, or the formation of ternary 
complexes, where serum reductants (e.g., ascorbate) may reduce the metal center. In 
particular, chloride ions are often considered to be coordinating ligands (Pt(II), Ru(III), and 
Rh(III)), which can influence the aquation and hydrolysis of metal complexes [180]. Analyses 
of samples from in vivo treated animals or patients have unambiguously demonstrated the key 
roles of serum proteins in the distribution of numerous antitumor metallodrugs. For example, 
the Ru(III) complex NKP-1339 binds with HSA as the major serum binder, where rapid non-
covalent binding to this protein protects the complex against reduction and hydrolysis, which 
may contribute to the low frequency of side effects observed in clinical trials (see Section 
4.6.5). The slow formation of covalent bonds was also observed. However, the adverse effects 
of cisplatin are related to reactions between the drug and serum compounds, specifically 
proteins and S-containing peptides. Cisplatin predominantly binds to HSA in real-world 
samples, although the concentration of the free drug is highly dependent on time (up to 90% 
of Pt(II) is bound to proteins at 3 h after infusion) [180]. Most of the Pt(II) is covalently 
bound and the coordination of the protein donor atoms (and thus the exchange of the original 
ligand(s)) is slow due to the kinetically more inert feature of the metal ion. The protein 
binding profile is different for the three Pt(II) drugs, where the level of protein binding is the 
lowest for carboplatin, and oxaliplatin preserves its original form most poorly in the unbound 
fraction [180,181]. Protein binding occurs slowly in the unbound fraction so the Pt(II) 
complexes are affected by various transformation processes such as aquation (Cl‒/H2O 
exchange, cisplatin), oxalate chain loosening (oxaliplatin), and reactions with small peptides 
(glutathione (GSH)) and AAs (Cys, Met) [180], which are also time-dependent processes. 
Unfortunately, comparative binding data are not available for the HSA adducts of the three 
Pt(II) complexes, although large variations have been reported regarding the number of 
binding sites (up to 5–12) and binding constants [178,180,182,183] for the “old” drug 
cisplatin. The major binding site of cisplatin on HSA probably involves a (S(Met298),N) 
macrochelate [183], and logKHSA = 3.88 and 4.17 were reported for cisplatin and oxaliplatin, 
respectively, by Rudnev et al. [182]. Thus, estimating the distribution in such complex 
systems would be difficult under non-equilibrium conditions. 
By contrast, for the kinetically more labile Ga(III) complexes, the serum distribution 
can be modeled mathematically using stability data. Numerous Ga(III) complexes have been 
developed as antitumor agents, where tris(8-quinolinolato)gallium(III) (KP46) and 
tris(maltolato)gallium(III) (GaM) are the most promising orally active agents that are 
currently undergoing clinical trials. The serum distributions were computed for KP46 and 
GaM complexes based on their solution stability and interactions with serum components. 
Despite the structural similarities of these Ga(III) complexes, KP46 has a stability constant 
that is about eight orders of magnitude higher than that of GaM, with much higher 
lipophilicity [43]. These features have major effects on their binding processes with serum 
proteins [35]. GaM does not bind to HSA, but moderate binding between KP46 and HSA via 
non-covalent bond while retaining the coordination environment around the metal ion was 
demonstrated (log K′ = 4.04) based on fluorometric and saturation transfer difference NMR 
measurements. The binding of KP46 with the protein occurs via the IB binding site according 
to modeling calculations. Tf can compete for Ga(III) with the carrier ligands of the 
complexes, but substitution by maltol occurs to a much higher extent compared with that by 
8-quinolinol. Based on these findings, equilibrium modeling calculations of the biospeciation 
of KP46 and GaM were performed for Ga(III)‒ligand‒HSA‒Tf systems. The stability 
constants of the following species were used in the calculations: associates present in the 
Ga(III)‒ligand systems (GaL, GaL2, GaL3, HL, H2L, and Ga(OH)i=1–4), KP46-HSA and 
maltol-HSA adducts, and Ga(III) complexes of Tf (GaTf, Ga2Tf). The effect of the LMM 
components on the distribution was negligible. Unambiguously different distributions were 
obtained for KP46 and GaM. Tf has a significant role in the case of GaM and the protein can 
replace maltol completely at concentrations lower than 30 μM. By contrast, the binding of 
KP46 to HSA is estimated under physiologically relevant conditions (Figure 8.). The binding 
of KP46 to HSA is reversible and does not alter the original coordination mode of the 
complex, which might increase its solubility and half-life. This finding also suggests a Tf-
independent gallium uptake mechanism for KP46 [35]. 
 
 
 
 
Fig. 8 Concentration distribution curves for the Ga(III) complex–HSA–Tf systems as a 
function of the analytical concentrations of the complex for KP46 (a) and GaM (b). Dashed 
lines denote the KP46 concentration range over the solubility limit. (pH = 7.4; cHSA = 630 μM, 
cTf = 37 μM considering that 30% of the binding sites of Tf are saturated with Fe(III)) 
Adapted from Ref. [35] 
 
Therefore, in addition to investigating the reaction rate, the extent of binding 
(determination of binding constants when an equilibrium is reached) and the nature of the 
binding event (non-covalent/coordinative) are important for successful drug development. 
 
4.5. Speciation investigations with a magnetic resonance imaging (MRI) contrast 
agent 
MRI is a medical imaging technique used for diagnosis by imaging the anatomy and 
physiological processes in the body. MRI has a wide range of applications in medical 
diagnosis and over 25,000 scanners are estimated to be in use worldwide [184]. MRI is based 
on NMR, where the most frequently studied nucleus is 1H. By varying the parameters of the 
pulse sequence, different contrasts can be generated between tissues due to the relaxation 
properties of the hydrogen atoms present. A contrast agent usually shortens, or in some cases 
increases, the value of T1 (spin-lattice relaxation time) for nearby water protons, thereby 
altering the contrast of the image [185]. Around 30–40% of clinical MRI applications use 
paramagnetic complexes (or superparamagnetic, ferromagnetic substances) as contrast agents 
[186]. The trivalent Gd(III) is the most efficient relaxation agent among all the paramagnetic 
cations due to its high electron spin (S = 7/2) and slow electron spin relaxation. Other 
paramagnetic metal ions have also been considered as MRI contrast agents, particularly the 
non-toxic biocompatible manganese(II) (S = 5/2) [187]. 
The free Gd(III) ion is toxic [188] so it must be chelated with appropriate multidentate 
ligands, which ensure high thermodynamic stability and/or kinetic inertness. The majority of 
clinical Gd(III)-based agents, which represent around 90% of all clinical contrast agent 
injections, have low molecular weight, an extracellular space localization, and they are non-
specific [186]. At present, nine different Gd(III)-aminopolycarboxylate complexes are used in 
clinics, which are mainly derivatives of the open chain H5DTPA 
(diethylenetriaminepentaacetic acid) or the macrocyclic H4DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) [189,190] (Fig. 9). 
The increasing clinical use of Gd(III)-based contrast agents was halted in 2006 when the 
development of a newly observed disease called nephrogenic systemic fibrosis (NSF) was 
assumed to be related to the use of Gd(III) [191,192]. NSF is a very rare, highly debilitating, 
life-threatening disease, which was observed only in patients with severe or end-stage renal 
disease [191-198]. The number of NSF cases reported by the end of 2007 was around 400, but 
due to the recommendations of health authorities, the number of cases decreased dramatically 
and no new cases have been reported [194,199,200]. About 75–80% of the known NSF cases 
could be associated with the use of Omniscan ([Gd(DTPA-BMA)], where BMA = bis-
(methylamide)) whereas far fewer disease have been reported in patients treated with 
Magnevist ([Gd(DTPA)]), and only a few cases have been observed after the use of 
macrocyclic agents [191,198,201-205]. 
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Fig. 9 Chemical structures of ligands, formulae, and trade names of Gd(III) complexes used 
as contrast agents (NMG: N-methylglucosamine). 
 
In body fluids, many metal ions and ligands may compete with the Gd(III) ion and the 
DTPA-BMA3 ligand, respectively. Equilibrium calculations have been performed using a 
simplified plasma model including the Cu(II)/Zn(II)/Ca(II) cations, AAs (Ala, Cys, Glu, Gly, 
His, and Lys), HSA, Tf, and small biomolecules (carbonate, phosphate, citrate, lactate, 
malate, and succinate) [206]. The model predicted that under physiological conditions (pH = 
7.4; t = 37°C; I = 0.15 NaCl), the phosphate ion is the only endogenous ligand that can 
compete with DTPA-BMA3. Approximately 17% of the [Gd(DTPA-BMA)] dissociates to 
form Gd(PO4) as a precipitate. The ligand DTPA-BMA is also released and it can form 
complexes with endogenous metal ions, so Zn(II), Cu(II), and Ca(II) ions may form 
complexes. Due to the relatively high concentration of the contrast agent (0.35 mM), the free 
DTPA-BMA can collect approximately ~80% of the serum Zn(II) and ~90% of the Cu(II) 
[206]. 
However, the dissociation of [Gd(DTPA-BMA)] in human serum is controlled 
kinetically rather than thermodynamically. The dissociation of the complex occurs alongside 
its elimination from the body, where the amount of Gd(III) released from [Gd(DTPA-BMA)] 
in body fluids depends on the rate of dissociation and elimination of the complex. An open 
two-compartment model was developed to assess the amounts of Gd(III) released in body 
fluids based on rate data obtained from pharmacokinetic studies of the elimination of 
[Gd(DTPA-BMA)] and rate data characterizing the dissociation of the Gd(III) complex. 
In patients with normal renal function, rate data indicate the elimination of about 95% 
of the administered [Gd(DTPA-BMA)] within about 48 h. In patients with severe renal 
impairment, the elimination of [Gd(DTPA-BMA)] is slow (t1/2 ~30–40 h) and during the long 
residence period, large amounts of the complex may dissociate so significant amounts of 
Gd(III) (approximately 12.5% in 5 days after the administration) can be deposited in the body 
[206]. 
 
4.6. Kinetic aspects of speciation in biology 
In terms of trace element speciation, in addition to thermodynamic stability, kinetic 
factors strongly affect the occurrence of species in a biological system, organ, organ 
compartment, etc. The ligand exchange reactions of different metal ions are variable and their 
rate is influenced greatly by the chemical environment where the metal ion occurs. The 
following general rule is valid for the lability of metal ions bound in various chemical forms 
in biological systems: aqua ions > inorganic ligands > LMM > HMM. The mobility of metal 
ions may also depend on their oxidation state. For example, chromium with an oxidation state 
of six has high mobility and relatively fast absorption, whereas it is one of the most inert 
transition metal ions with an oxidation state of three. Chromium is sold in drug stores as a 
nutrient and it leaves the body in the same form consumed due to its extreme inertness. 
However, if a small proportion is reduced to an oxidation state of two, then it catalyzes the 
ligand exchange reaction and the chromium might be absorbed, although there is no 
sufficiently strong reducing agent in the body that can reduce Cr(III) to Cr(II). The next 
sections provide a few examples where the different rates of various reactions in biological 
milieu cause significant changes in the speciation of biological fluids or tissues. 
 
4.6.1. Speciation of Al(III) in blood serum: citrate vs. phosphate 
As discussed above, the slow formation of oligomeric species of Al(III) with some 
LMM components can lead to uncertainty regarding the serum distribution of Al(III) [133]. 
According to NMR, Al(III) readily forms mononuclear mono and bis complexes where after 
mixing, the components oligomerize into a trinuclear complex in a rather slow process [207]. 
Furthermore, if phosphate is also present, ternary species predominate throughout the whole 
pH range from mixing until the actual thermodynamic equilibrium is reached. Time only 
affects the concentration of the trinuclear species, which is formed in a rather slow process 
from the mononuclear species [208]. Interestingly, if phosphate is added to this solution at 
least in a twofold excess, the monodentate phosphate can displace the tridentate citrate from 
the oligomeric complex over a longer period, where the characteristic quartet of the free 
citrate is present in the 1H NMR spectrum (Fig. 10) [208]. 
 
 
 
Fig. 10 1H NMR spectra recorded during the decomposition of the trinuclear Al(III)-citrate 
complex at pH 7.4. Spectrum of the trinuclear species [Al3(citrateH‒1)3(OH)]
4‒ at 10 mM (a), 
10 h (b), and 5 days (c) after adding a twofold excess of phosphate. Adapted from Ref. [208]. 
 
Modeling calculations have shown that at thermodynamic equilibrium, phosphate seems 
to be the most efficient binder of Al(III) (75%) in serum, although citrate-bound Al(III) also 
occurs at a significant concentration (20%), [208] which was confirmed by Bell et al. [209] 
who detected Al-bound citrate in native serum by 1H NMR, whereas the remainder was 
present in the ternary species. Similarly, Bantan et al. investigated the speciation of LMM 
Al(III) complexes in human serum by liquid chromatography and ESI-MS. In agreement with 
the results described above, they found three main Al(III) species present in serum: Al(III)-
citrate, Al(III)-phosphate, and the ternary Al(III)-citrate-phosphate [210]. 
In a more elegant manner, a computer-assisted real-time model was used by Beardmore 
and Exley to describe the distribution of sluggish metal ions in biological systems, such as 
Al(III) in serum [211]. As shown in Fig. 11, their model basically agrees with the semi-
quantitative treatment discussed above, where LMM citrate is another important binder as 
well as Tf during the whole period after the addition of Al(III). Their model also predicted a 
significant role for the formation of an aluminum hydroxide phase, which was substituted in 
the other model by a phosphate-hydroxido ternary Al(III)BH-1 (Al(III)PO4(OH)) phase. In 
addition, it should be mentioned that this other model omitted the pH and time ranges when 
the precipitation of solid materials occurs in the system. 
 
  
Fig. 11 Distribution of Al(III) between blood serum components as a function of time. 
Adapted from Ref. [211]. 
 
4.6.2. Speciation of Ca(II) in saliva 
This example considers some quantitative details regarding the demineralization-
remineralization equilibrium of tooth enamel [212]. Saliva is a complex biofluid, which 
contains inorganic anions, cations, nonelectrolytes, AAs, proteins, carbohydrates, and lipids. 
The pH of saliva is close to neutral in the absence of dietary acids. 
The major inorganic component of tooth enamel is hydroxyapatite (HAP; 
Ca5(PO4)3(OH)). Several other types of calcium phosphates may also precipitate in the mouth, 
including tricalcium phosphate (TCP; Ca3(PO4)2), tetracalcium phosphate (Ca4H(PO4)3), and 
calcium hydrogenphosphate (CP; CaHPO4). If fluoride is present, the 
demineralization‒remineralization equilibrium is influenced greatly by the formation of 
fluoroapatite (FAP; Ca5(PO4)3F), which has much lower solubility and thus it is formed in the 
remineralization process. Saliva continuously provides calcium and phosphate to the surfaces 
of the teeth at concentrations that cannot inhibit the demineralization caused by acids in dental 
plaque (but that also facilitate some remineralization), or at least halt the early stages of 
carious lesion formation (enamel demineralization). Table 7 shows the major calcium species 
in saliva [212]. 
 
Table 7 
Predicted Ca(II) phosphate species at various pH values in saliva based on model calculations 
(based on data in Refs. [212-214]).a 
 
pH long-term model short-term model 
5.00 FAP Ca2+ and Ca(citrate)
‒ 
6.00 FAP and HAP Ca2+ and Ca(citrate)‒ 
6.75 FAP and HAP TCP and CP 
7.00 FAP and HAP TCP and CP 
a Abbreviations in the table, FAP: Ca5(PO4)3F, HAP: 
Ca5(PO4)3(OH), TCP: Ca3(PO4)2, CP: CaHPO4. 
 
The thermodynamically most stable apatites form slowly from more readily precipitated 
precursors, so the model that includes apatites is called the long-term model, whereas the 
other without HAP and FAP is called the short-term model. The former may be considered as 
an equilibrium model of the system, whereas kinetic factors inhibit the direct formation of 
apatites in the latter. Computer modeling calculations suggest that CP and TCP are the most 
likely precursors of HAP. 
 
4.6.3. Interactions of Pd(II) complexes with nucleotides and thioether ligands 
Numerous Pt(II) complexes are used widely as anticancer agents, where their antitumor 
activity is related to the platination of DNA by interacting with guanine bases. However, it is 
also clear that platinum-sulfur interactions may also play significant roles in both the transport 
and nephrotoxicity of Pt(II)-containing agents. Previous studies of thioether and nucleobase 
complexes of Pt(II) demonstrate that the two types of donor sites are opposed in terms of their 
kinetic and thermodynamic behavior. The thioether adducts form relatively rapidly, which 
results in the formation of various metastable species, whereas they are readily substituted by 
various nitrogen donors in the equilibrium state. However, the very slow formation kinetics of 
Pt(II) complexes make it very difficult to describe these systems. Thus, Sóvágó et al. [215] 
used the corresponding Pd(II) systems to study the time-dependence of metal ion speciation, 
where they determined the thermodynamics and kinetics of PdL complexes with monodentate 
N-alkyl nucleobases (N) and thioether ligands (S). In PdL, L denotes a tridentate chelating 
agent, diethylenetriamine (dien) or terpyridine (terpy), which form very stable complexes with 
Pd(II) and leave a single coordination position empty around the metal ion, thereby allowing 
further substitution. Ternary complexes of the N donors have thermodynamic stability 
constants that are about three orders of magnitude higher than those of the thioether 
complexes, but the rate constants of the substitution reactions show that the formation of 
thioether complexes is faster by at least a factor of 10 [216-218]. The combined application of 
thermodynamic and kinetic parameters yielded the time-dependent speciation process shown 
in Fig 12. 
 
 
 
Fig. 12 Concentration of thioether- and nitrogen-bonded adducts as a function of time in 
binary systems obtained by mixing Pd(dien) and acetyl-methionine (AcMet) or cytidine (cyt) 
at a ratio of 1:2. Adapted from Ref. [215] 
 
The thermodynamic equilibrium state of this multicomponent system is characterized by 
the coordination of N-donors, which supports the assumption that the Pt-S bonds formed by 
platinum anticancer agents can play roles in the transport and toxicity of platinum drugs. 
These findings and the relative ratio of the ligand exchange rate constants for Pd(II) and Pt(II) 
(~105) indicate that the maximum formation of Pt-S bonded species should occur within a few 
hours, whereas the equilibrium should require a few months. It is unclear where the Pt(II) 
compounds will be located such a long period after administration. These results are not very 
promising in terms of the actual speciation of anticancer Pt(II) compounds in biology, and 
thus their efficacy. 
 
4.6.4. Transport of Cu(II) from complexes with His-containing peptides to Cys 
Cu transport in the blood has been studied extensively [219,220], where 64Cu isotope 
experiments have shown that most of the Cu bound to ceruloplasmin is not exchangeable, 
whereas that bound to HSA is exchangeable with LMM Cu carriers, such as AAs. The 
resulting complexes formed with AAs are considered important as Cu carriers through 
membranes (Eq. 5) [221]. 
 
Cu(II)-HSA + AA ↔ Cu(II)-HSA-AA ↔ Cu(AA)2 ↔ membrane Cu(I) species (5) 
 
Recent findings have greatly improved our understanding of Cu transport in cells. In 
particular, studies of many intracellular Cu proteins, e.g., Cu-MRI, have clarified the 
relationships between Cu transport and different genetic disorders such as Menkes disease 
[222]. These studies demonstrate that in addition to passive transport, other pathways through 
the membrane might involve ATPase. The Cu form inside cells is Cu(I), whereas that outside 
cells is Cu(II). The conversion mechanism involving a redox reaction remains unclear, but 
Cu(II) is assumed to be reduced by a thiol compound, such as Cys, GSH, or a Cu transport 
protein. Reduction is the force that drives Cu into the cell, so its speciation and mechanism 
are important for understanding Cu transport through membranes. 
Cu(II) is bound to HSA by the N-terminal moiety in a 4N (NH2, 2×amide-N
–, 
imidazole-N) manner, where it forms a stable complex with λmax in a similar manner to 
Cu(II)-GlyGlyHis [223]. Thus, His-containing tripeptides provide a good model of HSA 
binding to Cu(II). Kinetic studies of various peptides with Cys using stopped flow methods 
determined the following reaction path (Eq. 6) [224]. 
 
Cu(II)-peptide + AA ↔ Cu(II)-peptide-Cys ↔ Cu(II)(Cys)2 ↔ Cu(I) species (6) 
 
This reaction is similar to the ligand substitution reaction (Eq. 5), but the Cu(I) complex 
is formed in solution. Before the reduction of Cu(II), the formation of the ternary complex can 
be used to obtain information about Cu transport. For the Cu(II)-GlyGlyGly CuLH-2 complex, 
Cys-SH first attacks the carboxylate site (the fourth coordination site of CuH-2L) and Cys is 
bound in a monodentate manner in the ternary complex CuLH-2Cys [49]. For the Cu(II)-
GlyGlyGly system, the ternary complex forms rapidly, but a brief decrease in ternary complex 
formation can be observed based on the spectra as the reaction proceeds (Eq. 6). Surprisingly, 
in the presence of Cys, the Cu(II)–GlyGlyHis complex has the spectrum of the binary 
complex and the spectrum of the ternary complex is not observed [225]. This is due to the 
relatively slow formation of the ternary complex and because Cu(II) changes rapidly into the 
Cu(I) species (see Fig. 13.) 
 
 
Fig. 13 Time-dependent distribution of the Cu species formed during the reaction of 
[Cu(GlyGlyHisH-2)] with Cys at pH 8.7. Adapted from Ref. [226]. 
 
The slow ternary complex formation can be attributed to the strong Cu(II)-imidazole 
bond at the fourth coordination site, which stabilizes the two amide-N- bonds. The kinetic 
constants for the reaction from the ternary complex to Cu(I) are similar for each system that 
has been studied. The pH-dependence of the kinetic constant for ternary complex formation 
suggests that formation of the adduct occurs with concomitant H+ transfer. H+ uptake by the 
deprotonated peptide bond to obtain CuLH-1Cys is probably the limiting factor. In the case of 
GlyGlyHis, the CuH-2L complex is considered to be a poor H
+ acceptor, because the two 
amide-N units are stabilized by two strong anchor donors, i.e., NH2 and imidazole. The 
resulting coordination mode of the ternary complex Cu(II)‒GlyGlyHis‒Cys differs from that 
of other peptides, and the less favored formation protects against free radicals as side-products 
of the redox reaction. Thus, Cu is transported readily from the albumin model peptide to Cys 
via the ternary complex and then reduced to Cu(I) [223]. 
 
4.6.5. Anticancer Ru(III) complexes in serum 
Among the non-platinum tumor-inhibiting agents, two Ru(III) complexes are currently 
being clinically tested, i.e., imidazolium [trans-tetrachloro (dmso)(imidazole) ruthenate(III)] 
(NAMI-A) (where dmso = dimethyl sulfoxide) and sodium [trans-tetrachloridobis(1H-
indazole)ruthenate(III)] (NKP-1339) (see Fig. 14) [227,228]. The indazolium salt analogue of 
NKP-1339 (KP1019) is the most promising Ru-based agent and it has completed a phase-I 
study, although it has low water solubility, which limits the maximum dosage [227,229]. 
NKP-1339 and NAMI-A are administered intravenously, and they have quite distinct modes 
of action despite their structural similarities. NKP-1339 is active against solid tumors with 
minor side effects [227], whereas NAMI-A is directed against the metastasis process with a 
current focus on lung cancer [228]. These Ru(III) complexes have different hydrolytic 
properties (aquation and hydrolysis) and binding abilities with serum proteins in terms of the 
kinetics and thermodynamics of these processes. The rate of aquation (Cl‒/H2O exchange) of 
these Ru(III) complexes is affected greatly by the pH, temperature, and the concentrations of 
chloride and HCO3
‒ ions [230, 231], while their redox potentials are in the range of 
physiological reductants [227]. Thus, aquation and reduction, e.g., by ascorbate, may be 
possible under the serum conditions, although the binding to serum proteins hinders the 
efficiency of these processes [231, 232]. In addition, serum protein binding has significant 
effects on biodistribution, the half-life in the circulation, and clearance, which ultimately 
affect the pharmacokinetic profile of the drug. Furthermore, HSA and Tf can act as drug 
carriers (see Section 4.3), thereby justifying further studies of the interactions by NKP-1339 
and NAMI-A with these proteins. 
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 Fig. 14 Chemical structures of Ru(III) complexes in clinical development: NKP-1339 
(KP1019) and NAMI-A. 
 
The rapid binding of NKP-1339 to both Tf and HSA has been reported [231-235], 
although few studies have determined the binding rate constants for the interactions between 
Ru(III) complexes and proteins. The reaction rates of KP1019 with HSA and apoTf were 
determined using the CZE‒ICP(MS) method (kHSA = 10.6 × 10
–4 s–1, kapoTf = 28.7 × 10
–4 s–1), 
which demonstrated the kinetically more favorable binding with apoTf [236]. By contrast the 
much slower binding of KP1019 with apoTf via covalent bonds was shown by Walsby et al. 
using EPR spectroscopy [232]. In general, KP1019 and NKP-1339 are described as being 
bound to HSA in both in vitro human serum and in vivo samples obtained from treated 
patients [227,232,236-238, see Fig. 15]. First, the complex NKP-1339 (and KP1019) binds to 
HSA in a non-covalent manner due to the axial indazole ligand’s interaction with the 
hydrophobic pockets according to EPR measurements [232]. The binding at sites IIA and IIIA 
has moderate strength (logKHSA= 5.3‒5.8) regardless of the counter-ions, according to 
combined analyses using ultrafiltration-UV, CZE, and fluorescence spectroscopy (with direct 
and displacement reactions of the site markers) [233]. However, with longer incubation times, 
NKP-1339 (and KP1019) is converted into a covalently (coordinatively) bound species. The 
slow binding of the complex to the side chain donor atoms of HSA via ligand exchange 
(Cl‒/His nitrogen atoms) may explain the relatively high kinetic inertness of Ru(III) [232]. 
Therefore, the delivery of NKP-1339 by HSA to cancer cells is assumed to be followed by the 
enzymatic degradation of HSA and reduction of the Ru(III) complex in the hypoxic 
environment that is often found in solid tumors because of insufficient tumor vascularization 
[227]. Reduction leads to the formation of the kinetically more labile Ru(II) complex, which 
is more capable of reacting with diverse targets (proteins and DNA). The mode of action of 
NKP-1339 is still unclear, but different factors such as endoplasmic reticulum stress are 
involved [239]. 
  
Fig. 15 CE‒ICP(MS) monitoring of the binding kinetics for the interaction of KP1019 with 
HSA and Tf (a). Reproduced from Ref. [236]. Comparison of the in vitro binding kinetics of 
KP1019 with HSA: circles, HSA; triangles, human serum; squares, human plasma (b). 
Reproduced from Ref. [238]. 
 
The coordinating N-donor ligand (indazole) has a prominent role according to the rate 
and extent of the transport and transformation processes determined for NKP-1339. 
Modifications of this axial ligand affect numerous properties, such as solubility, lipophilicity, 
and the ligand exchange rate, as well as the ability to bind to HSA and the redox potential of 
the complex, where all these factors ultimately influence the bioactivity [240,241]. 
The kinetic trans-effect of the coordinating S-donor dmso ligand in the complex NAMI-
A leads to increased lability and a lower redox potential compared with NKP-1339, where 
these properties make this complex more amenable to hydrolysis and reduction in biological 
media [231,235,242,243]. NAMI-A also has a high affinity for serum proteins. Rapid binding 
to Tf was reported by Speiewak et al. because the equilibrium could be reached within 5 min 
in fluorescence Tyr quenching experiments [234]. Binding constants of logK = 4.11 
[234,244] and 4.01 [234] were determined for apoTf and holoTf, respectively, and 
coordination at other sites was suggested in addition to the Fe(III) binding sites [234]. Similar 
to NKP-1339, HSA is also the major binder for NAMI-A in blood serum. EPR experiments 
by Web et al. [231, 235] indicated rapid binding to HSA in hydrophobic pockets via non-
covalent bonds. HSA binding could prevent the reduction of NAMI-A by ascorbate in the 
serum. The coordination of the His imidazole ligands of the protein was confirmed by 
ENDOR spectroscopy with a longer incubation time [235]. 
 
 
a b 
5. Outlook 
 Speciation in inert systems refers to the full separation of species and their complete 
structural identification. This process is entirely different compared with that for labile 
systems and it involves preparative work, possibly including the application of separation 
techniques and structural investigation methods in the solid state. 
 Solution speciation where mostly labile species are in equilibrium with each other and 
their species distribution is strongly dependent on the experimental conditions is a different 
issue. The aims of these studies are as follows: (i) obtaining full descriptions of the equilibria, 
including the distribution of the species in the equilibrium system and determining their 
characteristics, such as solution structures (binding modes) of the species that are in 
equilibrium with each other; and (ii) using equilibrium descriptions of these systems in 
modeling calculations to determine the species distributions of the constituents in conditions 
where experimental measurements cannot obtain data, e.g., due to extremely low 
analytical/total concentrations. At present, there is no clear boundary between these two 
objectives, which may cause difficulties for chemists. 
In trace analytical chemistry, speciation is applied widely and it is a rapidly developing 
area of analytical chemistry. Environmental, medical, and industrial problems will probably 
force this field to make further improvements in the future, e.g., lowering the detection limits 
and achieving even better separation of parallel existing species. However, this type of 
speciation is possible to determine only using certain types of “samples” because in situ 
spectral measurements can only indicate the distribution of one species (or a group of species) 
or elements on the surface, e.g., complete speciation might not possible in a certain area. For 
example, fluorescent dyes [245] were developed to detect “free” Cu(I) in cells using a 
microscope, but no method can determine the complete speciation of copper and measure 
each of the four species groups at the same time, i.e., the free and bound copper in oxidation 
states I and II. 
Similar to trace analytical speciation, many analytical techniques have been developed 
to detect different chemical species on surfaces, e.g., X-ray photoelectron spectroscopy, 
reflection-absorption IR spectroscopy, secondary ion-MS, temperature-programmed 
techniques, and microscopy techniques such as atomic force microscopy. 
As classic studies of complex formation, speciation studies are not “fashionable” at 
present. For example, the number of annual publications containing pH-potentiometric studies 
has increased only slightly in recent decades but at a much slower rate than the total number 
of coordination chemistry publications [60]. Moreover, these studies are increasingly difficult 
to publish in highly ranked journals, especially if they are not combined with other methods. 
The opinion of the scientific community is that speciation can be performed routinely and that 
stability constant data should be published only in second/third ranked journals. The relatively 
low “prestige” of these data does not help to improve the reliability of published speciation 
data. However, reliable and accurate published data are of the utmost importance for any type 
of chemical project. 
Published speciation data are collected in the IUPAC Stability Constants Database [37], 
which is used mostly by specialists. However, the browsability (e.g., conditional stability 
constant), parameterization of the speciation calculations (sometimes by hand), and reliability 
of the data collected in this database should be improved to make it more user-friendly and 
suitable for a wider range of potential users. 
When speciation studies started, potentiometric and photometric studies were the most 
common techniques, and evaluation programs were designed for these methods. With the 
exception of HYPERQUAD [246,247], most of these programs are now old-fashioned and 
not user-friendly. These programs lack input editors, so the input data must be pre-edited and 
the output is sometimes long and barely understandable to beginners. Graphics are absent or 
low quality, and the possibilities of modern hardware are not fully utilized. The operation 
systems used by PCs have changed greatly in the last decades and it may be difficult to even 
run these programs. The dramatically increased calculation capacity of computer hardware 
could be applied to automatic model selection and for identifying characteristic errors. In 
addition, the methods used to calculate the statistical parameters should be reconsidered. 
To the best of our knowledge, LAKE [248] is the only program that can handle the dual 
aspects of NMR spectral data together, i.e., the chemical shift and signal intensity data. The 
previously mentioned 2D-EPR program is also very inconvenient to operate [63], where the 
number of components is restricted to only three. No program can handle EPR and UV-Vis 
data together. Individual evaluations of the data obtained by different methods can yield 
numerically variant stability data sets, but it is sometimes quite difficult to judge which is 
more accurate. 
Thus, there is a need to develop a user-friendly program that can handle data obtained using 
different methods (e.g., pH-potentiometry, UV-Vis, CD, and EPR/NMR). The program 
should be able to evaluate all the input data together to obtain a stability data set, as well as 
describing EPR/NMR spectra measured according to certain parameters. The low reliably of 
some published data may be due to the incorrect statistical handling of the measurements. 
Therefore, reinterpretations of evaluations and the development of appropriate methods may 
be necessary to handle data obtained from multiple methods in order to provide correct 
information about the reliability of the component matrix and the stability constants 
determined. It would also be useful to assemble the speciation results in a database, including 
short published data sets as well as all the measurements, evaluations, and statistical 
parameters, in a similar manner to the Cambridge Structural Database (CSD) [249]. Clearly, 
determining the basic conditions of such a database is a major undertaking. In particular, 
many methods are employed for measuring equilibrium data compared with, for example, X-
ray studies. Thus, the pH calibration and calculation methods must be unified, or the number 
of types should be limited, as well as giving full descriptions of them. Initially, it might be 
easier to handle the data determined by only one method and to classify them based on the 
technique employed. However, due to the lack of new and publishable data, this database 
would probably grow quite slowly. 
Critical stability constant data compilations based on rigorous selection criteria and 
expert opinions may provide the stability data needed by non-specialists. These data have 
been obtained mostly in aqueous solution under normal, everyday conditions. However, there 
is a great need for stability data obtained in non-aqueous solutions, water-organic solvent 
mixtures, or unusual experimental conditions (pressure, temperature, or at extremely high 
concentrations), as well as in the presence of amphipathic molecules or other micelle-forming 
organic substances, and complex formation processes on the surfaces of solid materials. The 
latter cases also raise several theoretical issues, which should be clarified. For example, there 
is no complete description of labile surface processes, probably because the chemical 
environment of a simple species can be much more complex on the surface compared with 
that in a dilute solution. A surface does not necessarily have the same environment at every 
point and a species can have various connections to the surface, especially if the concentration 
of the species is sufficiently high to form more than one layer. Isotherms are measured 
routinely to determine the binding capacity of the surface [250], but titrations and kinetic 
consideration may also be required to determine concentration(s) [250]. Protonation processes 
[251] and simple complex formation reactions have been quantitatively described [252] on a 
surface, but few studies have described surface speciation [60]. 
Other problems include predicting stability data based on theoretical calculations [253], 
but this appears to be a long process at this stage and it is probably more accurate to estimate 
a protonation constant [254,255] by selecting one from a database rather than a theoretical 
calculation. 
Simple binary and ternary systems (e.g., the acid-base properties of a compound, or the 
formation of single ML type complexes with monodentate or bidentate ligands) can be 
measured easily, but evaluating complex systems (e.g., multidentate ligands form many types 
of complexes, such as via metal ion hydrolysis or by the formation of protonated complexes 
to produce quaternary systems) can be difficult even for specialists. Unfortunately, no system 
is available to address all of these problems. A speciation chemist ideally requires a program 
that can evaluate the data measurements as well as providing measurement plans based on 
previous results and giving theoretical predictions. Using the measurements, suggestions can 
be provided about how to make the experimental details more accurate. However, the 
community of speciation chemists and the potential users of speciation data might not be 
sufficiently large as a “market” to invest great efforts in the development of expert computer 
programs and systems. 
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Abbreviations 
 
2M  alpha-2-macroglobulin 
AA  amino acid 
acac  acetylacetone 
AcMet  acetyl-methionine 
apoTf  apotransferrin 
ATCUN amino terminal Cu(II) and Ni(II) binding side 
BMA  bis-(methylamide) 
CD  circular dichroism 
CP  calcium hydrogenphosphate 
cyt  cytidine 
CZE  capillary zone electrophoresis 
CZE-ICP-MS capillary zone electrophoresis inductively coupled plasma mass spectrometry 
dhp  1,2 dimethyl-3-hydroxy-4-pyridinone 
dien  diethylenetriamine 
DM  Diabetes mellitus 
dmso  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DOTA  tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DTPA  diethylenetriaminepentaacetic acid 
DTPA-BMA 1,7-Bis(methylcarbamoylmethyl)-1,4,7-triazaheptane-1,4,7-triacetic acid 
ENDOR electron nuclear double resonance 
EPR  electron paramagnetic resonance 
ESI-MS electrospray ionization-mass spectrometry 
FAP  fluoroapatite 
GaM  tris(maltolato)gallium(III) 
GSH  glutathione 
GI  gastrointestinal 
HAP  hydroxyapatite 
HMM  high molecular mass 
HPLC  high-performance liquid chromatography 
hpno  2-hydroxypyridine 1-oxide 
HSA  human serum albumin 
ICP-MS inductively coupled plasma-mass spectrometry 
Ig  Immunoglobulin 
IUPAC International Union of Pure and Applied Chemistry 
KP1019 indazolium [trans-tetrachloridobis(1H-indazole)ruthenate(III)] 
KP46  tris(8-quinolinolato)gallium(III) 
L  ligand of any kind in the fully deprotonated form; charge is usually omitted for 
simplicity 
LMM  low molecular mass  
M  metal ion; charge is usually omitted for simplicity 
mal  maltol 
MRI  magnetic resonance imaging 
MS  mass spectrometry 
nta  nitrilotriacetic acid 
NAMI-A  imidazolium [trans-tetrachloro(dmso)(imidazole)ruthenate(III)] 
NKP-1339 sodium [trans-tetrachloridobis(1H-indazole)ruthenate(III)] 
NMG  N-methyl-glucosamine 
NMR  nuclear magnetic resonance 
NSF  nephrogenic systemic fibrosis 
pic  picolinic acid 
TCP  tricalcium phosphate 
terpy  terpyridine 
Tf  human serum transferrin 
UV-Vis UV-visible 
XANES X-ray absorption near edge structure 
 
